438 Stem Cell Therapies Companies - Worldwide

London, England, United Kingdom

199 Biotechnologies is an early-stage
company developing first-in-class therapies that target the fundamental mechanisms of aging, with the goal of transforming the landscape of age-related disease treatment and prevention.

princeton, new jersey, united states

4M Therapeutics Inc. (4MTx) is developing targeted therapies for central nervous system (CNS) disorders. Our discovery platform was developed at Harvard, MIT and the University of Washington to uncover how drugs like lithium enhance the health of living human brain cells – and then to design better alternatives. Pre-clinical data show that our lead asset 4MT2001 has the potential to provide a better combination of efficacy and safety than lithium for the treatment of bipolar disorder (BPD). Clinical trials will begin in early 2025 as we seek to address a $6 billion US market. Beyond BPD, our pipeline has the potential to address Alzheimer's disease, frontal temporal dementia, and other brain disorders with broad clinical, commercial, and partnering potential. 4MTx is led by CEO Pablo Lapuerta, who has developed and launched multiple drugs. He introduced into clinical trials the first targeted CNS kinase inhibitor to show successful proof-of-concept data. Board Chair Don Hayden was previously President of Global Pharmaceuticals at Bristol Myers-Squibb and led the development and commercialization of CNS blockbuster Abilify (peak annual sales > $6B). Board member Dr. Lawrence Goldstein co-founded publicly-traded Cytokinetics and is professor emeritus at UC San Diego with extensive CNS experience.

Technologiepark-Zwijnaarde, 48, Ghent, 9052, BE

4Tissue is an innovation-led research and clinical development organization. Our mission is to redefine the boundaries of tissue reconstruction, regeneration, and anti-aging, utilizing innovative biocompatible and bioresorbable polymers platform The first product, a bioresorbable injectable hydrogel, is focused on a better cell survival and the full regeneration of adipose tissue for breast reconstruction and augmentation applications.

Houston, Texas, United States

7 Hills Pharma is a clinical-stage immunotherapy company developing a platform of novel, oral small molecules for the treatment of cancer and prevention of infectious diseases. Our compounds are first-in-concept allosteric integrin activators that leverage a unique mechanism of action to stabilize the cell-cell interactions required to mount an effective immune response. Our lead clinical candidate, 7HP349, is the only reported systemically safe immune stimulant that can activate both cellular and humoral immunity.

Évry, France

Specialized in cell culture, Abcell-bio has a 10-year background and experience in Stem Cell Research and Development. Abcell-bio team is composed of experts that can advise you for your research projects. Our technical team is trained to produce high-quality products in the fields of hematopoiesis and vascular biology. We can process several cell types extracted from: * Cord Blood: CD34+ cells, CD133+ cells, CD34- cells, MonoNuclear Cells (MNCs), Endothelial Progenitor Cells (EPCs) * Umbilical Cord (Human Umbilical Vein/Arterial Endothelial Cells (HUVEC, HUAEC) We also created Cell Culture Media to match your needs for these particular cell types. Please contact us for more information

San Diego, California, United States

Abcepta is a biotechnology company that specializes in developing primary antibodies and custom services for research and drug discovery.

3675 Market St, Suite 200, Philadelphia, Pennsylvania 19104, US

Accelerated Biosciences Corp. is commercializing human trophoblast stem cells isolated from the trophectoderm of embryos from women with ectopic pregnancies. hTSCs are ethically sourced and have immune-privileged characteristics. It is an abundant and dynamic pluripotent stem cell platform for basic research, disease modeling, toxicology, drug discovery, and cell therapy.

Alameda, California, United States

Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell Conjugation (ACC) technology, the company links tumor-targeting antibodies to its proprietary immune effector cells, such as gamma delta T cells and natural killer (NK) cells to create novel antibody cell effector (ACE) therapies, which have increased binding strength against tumors that express low levels of tumor antigens. Acepodia is made up of seasoned leadership and scientific experts dedicated to advancing its robust pipeline of off-the-shelf ACE therapies with the potential to bring powerful, accessible cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers.

Mainz, Germany

ActiTrexx GmbH is a new biotech start up and was founded in 2020. Our vision is to offer a curative cellular therapy to prevent inflammatory reactions in conditions like GvHD, solid organ transplantation and autoimmune diseases. Regulatory T cells (Treg) - natural guardian cells of the immune system - are the key players of our cell-based drug product. Isolated Treg are activated ex vivo via specific methods and administered to patients intravenously. Unlike other comparable approaches, activated Treg (ATreg) will not be expanded in vitro, protecting them against a possible loss of function. Thus, ATreg is a safe and efficient treatment option for transplanted patients preventing and providing substantial decrease of GvHD severity and related mortality as well. The founders of ActiTrexx GmbH combine many years of unique experience in basic research, biotechnology, clinical application and pharmaceutical development. The management team is supported and complemented by a strong network of collaborators, advisors and key opinion leaders as well as experienced managers.

Monrovia, California, United States

AcuraStem (acurastem.com) is a near-to-clinic, patient-based, drug development company pioneering drug discovery and ultimately how treatments are developed for neurodegenerative diseases—including sporadic ALS and FTD. Enabled by our ground-breaking iNeuroRx® technology platform - AcuraStem has discovered and is now advancing drug candidates that promise to strongly impact disease progression for most patients, including those for whom the genetic cause of their disease is unknown (i.e. sporadic ALS and FTD patients). The causes of neurodegenerative diseases are complex, and genetically defined forms of disease (e.g. C9ORF72-ALS and FTD) only account for a small percentage of cases. Thus, many scientists didn’t believe it was possible to develop a single effective treatment that could work broadly for all patients. But AcuraStem has shown with its extremely promising therapeutic programs for ALS and FTD that it can be done.

Noida, India

Advancells offers stem cells for various chronic conditions and lifestyle disorders.

Woburn, Massachusetts, United States

Aegle Therapeutics Corp. is a clinical-stage biotechnology company developing novel extracellular vesicle (“EV”) therapies to address rare and serious diseases and disorders with significant unmet medical needs. Aegle’s proprietary platform technology safely isolates native extracellular vesicles (“EVs”) from stem cells. These EVs carry complex assemblies of biologic molecules such as proteins and nucleic acids that can induce a wide variety of effects in recipient cells, including the promotion of regenerative healing, while reducing inflammation and modulating the immune system. Aegle’s EV therapy has the potential to treat a broad range of indications in multiple therapeutic areas, including dermatology, immunology-based diseases, protein deficient disorders and others.

Heidelberg, Germany

At Affimed, we are committed to improving outcomes for patients with cancer. Our scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unique approach to fighting cancer. With our unparalleled expertise in innate immunity and innate cell engager-based medicines, we aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.

Bonsall, California, United States

Agastiya Biotech merges advanced, Eastern knowledge with rigorous Western R&D in order to deliver breakthrough innovative pharmaceuticals to the marketplace. Over 40% of all pharmaceutical drugs, including sophisticated chemotherapy and anti-viral drugs, are derived from natural plant sources. Through investigation of ancient Eastern botanical knowledge combined with high throughput and AI driven analysis, Agastiya Biotech engineers best in class novel small molecules for treatment of disease. We are leading the discovery and design of ground-breaking small molecules to revolutionize medicine and find a cure for the diseases of our time.

Fargo, North Dakota, US

Agathos Biologics is a biotechnology company pursuing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy. Discoveries in bioprocessing and genetic characterization and control have created an abundance of scientific possibilities that can help us all lead better lives. Our mission as the good science company is to create breakthrough products and services within a strong ethical and moral framework that benefit everyone. We believe in science that serves and have a relentless focus on serving our clients, employees, and society. For more information, please visitÂ

Las Vegas

Ageless Biotech (ABT) is in the development of discardable, minimally manipulated umbilical tissue based regenerative medicine biologics to address all forms of Osteoarthritis via intra-articular procedures in cooperation with leading scientists and medical professionals. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives. We believe that the formation of life itself is contained within after birth tissues. ABT believes that it is morally, religiously and politically acceptable to use afterbirth materials that would be considered discardable in virtually every country. Furthermore, we believe this to be the right course to addressing problems that a vast majority of the population will face at some point during their lifespan.

Vienna, Austria

a:head’s drug discovery approach is based on human cerebral organoids, a revolutionary, paradigm-shifting new technology that allows the generation of mini brains from human stem cells in vitro. They capture the essential aspects of human embryonic brain development including brain patterning, formation of brain ventricles, differentiation into the various neuronal and supportive cell types and their correct three-dimensional arrangement. The technology has been pioneered by the company’s co-founders Madeline Lancaster and Juergen Knoblich and is exclusively licensed to a:head by the Institute of Molecular Biotechnology, Vienna, Austria. a:head applies these complex 3D tissue cultures for modelling of various brain disorders in a human context and aims at translating the technology into a powerful high content, high throughput phenotyping platform for the development of novel CNS therapeutics.

Irvine, California, United States

AIVITA Biomedical is an Irvine, CA based company focused on the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. We leverage our unique expertise in stem cell growth and directed, high-purity differentiation to develop safe, efficient and economical manufacturing processes for therapeutic development. These proprietary capabilities enable us to turn therapeutic discovery into reality, developing revolutionary cell-based treatments and healthcare products for the patients who need them. AIVITA is developing treatments for cancer, vision loss, and is bringing next-generation skincare formulations to consumers through its commercial product offerings.

West Sussex, United Kingdom

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead product candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. Akari Therapeutics, Plc is based in London, the United Kingdom.

Hamilton, Ontario, Canada

Built on 30+ years of foundational expertise, Allarta’s proprietary platform is designed to overcome immune rejection, prevent cell escape and safely deliver cell and stem cell therapies. Our lead product is a cell therapy focused on type 1 diabetes (T1D) as a first indication.

San Diego, California, United States

Allele Biotechnology and Pharmaceuticals, Inc. is a private, San Diego-based company that explores the mechanisms of biological processes to develop technologies and products for biomedical researchers. The company was founded by scientists and other professionals with the goal of advancing discovery and innovation. Our mission is to increase accessibility to innovative molecular biology research tools by offering cutting edge products at a reasonable cost, and providing excellent customer service in addition to the technical knowledge needed to facilitate their use. Our knowledgeable scientists and technicians are available to answer questions regarding any of our products. Over the past decade, Allele has become a reliable source for a wide variety of Molecular Biology reagents, superior fluorescent proteins, camelid derived nano antibodies (nAb), cellular reprogramming services and reagents, and immundiagnostic kits and various other products and custom services.

615 Westlake Ave N, Seattle, Washington 98109, US

The mission of the Allen Institute is to unlock the complexities of bioscience and advance our knowledge to improve human health. Using an open science, multi-scale, team approach, the Allen Institute focuses on accelerating foundational research, developing standards and models, and cultivating new ideas to make a broad, transformational impact on science. Founded by philanthropist and visionary Paul G. Allen, the Allen Institute is a recognized leader in large-scale, open science research. Its research institutes include the Allen Institute for Brain Science, Allen Institute for Cell Science, Allen Institute for Immunology and The Paul G. Allen Frontiers Group. The Allen Institute believes that team science significantly benefits from the participation of diverse voices, experiences and backgrounds. High-quality science can only be produced when it includes different perspectives. We are committed to increasing diversity across every team and encourage people from all backgrounds to apply for our open positions.

Lyon, France

At Allogenica, we are transforming cell therapies for a healthier tomorrow. Our mission is to 𝗱𝗶𝘀𝗿𝘂𝗽𝘁 𝘁𝗵𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝗳𝗼𝗿 𝗰𝗮𝗻𝗰𝗲𝗿, 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀, 𝗮𝗻𝗱 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗼𝗿𝗱𝗲𝗿𝘀. We're developing a breakthrough cell therapy platform with the potential to: • 𝗥𝗲𝗽𝗹𝗮𝗰𝗲 𝘁𝗿𝗮𝗻𝘀𝗽𝗹𝗮𝗻𝘁𝘀: Providing less invasive, accessible alternatives for thousands of patients who currently have limited treatment options. • 𝗘𝘅𝗽𝗮𝗻𝗱 𝗮𝗰𝗰𝗲𝘀𝘀 𝗳𝗼𝗿 𝗮𝗹𝗹: With predictable safety and efficacy, we aim to make cell therapies available to a a broader patient population. • 𝗗𝗿𝗮𝗺𝗮𝘁𝗶𝗰𝗮𝗹𝗹𝘆 𝗿𝗲𝗱𝘂𝗰𝗲 𝗰𝗼𝘀𝘁𝘀: By streamlining production, we aim to significantly lower the cost of cell therapies, making transformative treatments more accessible globally. 𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧 Founded in 2022, Allogenica has rapidly emerged as a pioneer in the field. Our innovative approach includes: • 𝗣𝗿𝗼𝗽𝗿𝗶𝗲𝘁𝗮𝗿𝘆 𝗣𝗿𝗲-𝗧 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀: Enhancing compatibility with patients' immune systems, reducing the risk of rejection. • 𝗦𝗰𝗮𝗹𝗮𝗯𝗹𝗲, 𝗕𝗿𝗼𝗮𝗱 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀: Our platform has the potential to treat a diverse range of diseases, ensuring scalability and reaching more patients in need. • 𝗖𝗼𝘀𝘁-𝗘𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲, 𝗥𝗮𝗽𝗶𝗱 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀: Delivering affordable and faster-to-market therapies, to change lives on a global scale, potentially impacting millions.

Maryland

Aloe Therapeutics is a biotech start-up aimed at delivering cancer cures. We have designed a therapy, termed Allo-Immunotherapy (AIM), to trigger an influx of activated immune cells to traffic to the tumor microenvironment - turning "cold" tumors "hot" and "hot" tumors "hotter." INFLAME WITH AIM.

Boston, Massachusetts, United States, Munich, Germany., Europe

Alphageneron Pharmaceuticals, Inc., is a privately-held clinical stage biotechnology company, developing Antibody Drug Conjugates (ADCs) and natural killer (NK) cell therapies, supported by Companion Diagnostics. Our team are industry veterans with experience in both large pharma and biotechnology startups committed to transforming the lives of cancer patients.

2600 Hilltop Dr, Richmond, California, US

ALSTEM is an early stage biotech company based in the San Francisco Bay Area specializing in Induced pluripotent stem cells and reprogramming technologies. Founded in early 2012 by a team of scientists with deep experience in both academic and industrial biotechnology, ALSTEM is advancing frontiers in genome editing, virus packaging, cell immortalization, and iPS cell technology.

Shelton, Connecticut

Altucell, Inc. is a cellular engineering and biotech company backed by sound research and science focused on fulfilling a large "unmet need" in cell, molecular and regenerative therapy for treatment of Diabetes and other autoimmune and neurodegenerative diseases. The company’s proprietary and unique technology overcomes the major barriers to transplantation by a novel strategy utilizing patented micro-encapsulation technology, enabling a transplantable, cell-based therapy that avoids detection and rejection by the immune system.

Boston, Massachusetts

At Amasa Therapeutics, we pioneer cell therapy and aim to radically improve the ways we treat the most malignant tumors. Our engineered cells are designed to revolutionize patient care and solve problems within oncology that are decades old.

Eatontown, New Jersey, United States

American CryoStem Corporation (CRYO) is a clinical-stage biotechnology company, developing and delivering autologous (own self) regenerative therapies to treat diseases and conditions with significant unmet medical needs. We are prioritizing research targets and biological drug candidates where the disease biology is understood, and where our suite of technologies has the potential to make a difference. We are currently focused on mitigating the deleterious effects of post-concussion syndrome: https://clinicaltrials.gov/ct2/show/NCT04744051 and Long COVID/ PASC: Post Acute Sequelae of SARS-CoV-2 https://clinicaltrials.gov/ct2/show/NCT05669261 Translating Technology into Therapeutic Treatments™ Our core proprietary "end-to-end" patented technology platform consists of the “Collection-Processing-Cryobanking and Delivery to Point-of-Care” of Adipose Tissue (AT) and Adipose-Derived Mesenchymal Stem Cells (MSCs). Our Platform is configured to produce large quantities of autologous mesenchymal stem cells for treatments as needed, "on-demand". Through a single tissue collection, an autologous master cell sample is manufactured and cryopreserved for a lifetime of personalized treatments. Naturally, pure and simple.™

Lund, Skåne, Sweden

Amniotics was born out of the discovery of novel stem cells in full term amniotic fluid. Research on these cells has demonstrated a number of unique properties in them, highlighting their extraordinary suitability for medical applications. These properties, in combination with safe collection, ethical agreeability, tissues and high cell counts harbour the promise of the exciting journey we have started pushing medical boundaries. The science and research behind the discoveries on which the company is based has been carried out within the realms of the reputable Lund University in southern Sweden, one of its prime research centers BMC (Bio Medical Center) Research Center, and the university hospital in Lund. Therefore, Amniotics considers itself today to be uniquely positioned to translate stem cell technologies into novel and improved human therapeutics. Our ultimate vision is to contribute to the successful treatment of serious human diseases by providing the very best cells for various regenerative medical applications. The fact that our cells are of neonatal source (and safely retrieved from the amniotic fluid from C-sections), means that they have greater genome integrity. And also other positive attributes of the neonatal source of our cells makes them superior to traditional sources of stem cells that are currently in therapeutic use. As part of our commitment to providing the best cell therapeutics we are developing these for treatments with high unmet needs in collaboration with international renowned KOLs and partners. In a nutshell, we have designed and built a complete ecosystem for managing these cells in a safe, secure and controlled manner, which we are now expanding and scaling up. Our journey continues. We will push the boundaries of science within regenerative medicine to save and improve the lives of many. #regenerativemedicine, #stemcells #therapies

Innsbruck, Tyrol, Austria

Angios is a biotechnology company, specializing in vascular research to improve patients' lives all over the world. We are based in the beautiful city of Innsbruck. We strive to develop new treatments for challenging diabetic vascular diseases by pursuing pre-identified targets for diabetic retinopathy and by leveraging the vascular organoid model developed in the laboratories of our founders.

San Diego, California, United States

Animal Cell Therapies engages in research and development of stem cell treatments for orthopedic and chronic diseases in dogs.

South San Francisco, California, United States

Stem cell renewal, maintenance and tissue regeneration are critical for normal health and well-being. Wnt pathway interactions are crucial to maintenance of these processes. Ankasa is the first to produce human Wnt proteins in a manufacturing setting suitable for use in humans, leading to clinical candidate ART352-L. Successful development of ART352-L will enhance the osteogenic properties of patient derived stem cells used in reconstructive surgeries and provide safe and effective enhancement of bone formation in indications for which this is a significant unmet medical need.

Vienna, Austria

Previously known as AOP Orphan, AOP Health is the European pioneer for integrated therapies for rare diseases and in critical care. Over the past 25 years, the company has become an established provider of integrated therapy solutions from its headquarters in Vienna, its subsidiaries and representative offices throughout Europe and the Middle East, as well as through partners worldwide. This development has been made possible by a continually high level of investment in research and development on the one hand and a highly consistent and pragmatic orientation towards the needs of all our stakeholders on the other - especially the patients and their families as well as also the doctors and care professionals treating them. Needs. Science. Trust. The international healthcare group focuses on research, development and global sales of innovative treatment solutions. AOP Health believes it has a responsibility to make innovative integrated therapies and disease-management solutions available long term to as many patients as possible who suffer from rare diseases or require critical care.

Culver City, California, United States

Appia Bio is an early stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).

Santa Clara, California, US

Applied Cells, Inc., was founded in 2018 in Silicon Valley to create revolutionary solutions to cell separation and enrichment products, which increase cell separation efficiently by changing how physics is employed in the process. We are supporting industry experts in Cell Therapy Development with MARS® immunomagnetic cell separation Platform. Our innovative, column-free, immunomagnetic cell iso

Milpitas, California, United States

Advancing Gene and Cell Product Development Through iPSC and Genome Editing Technologies Applied StemCell strives to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry to assist in the development of breakthrough therapeutic approaches to cure intractable diseases. ASC is a trailblazing CRO/CDMO committed to building a complete iPSC-Gene Editing platform for the production of iPSC-derived products for gene and cell therapy research and development. With the integration of our unique iPSC approach and IP-based site-specific large cargo insertion technology, TARGATT™, we (1) develop immune-compatible master iPS cell lines and (2) deliver large DNA fragments to pluripotent cells that have proven differentiation capabilities. We stand at the forefront of the iPSC-based therapy revolution delivering research- and GMP-grade iPSC solutions along with various downstream assay services. Current Offerings: • iPSC Cell Line Models: iPSC generation, CRISPR & TARGATT™ genome editing, differentiation • Cell Gene Product CDMO: TARGATT™ iPSC Platform for allogeneic cell therapy products/GMP iPSC reprogramming, cell banking, gene editing, and differentiation • Bioproduction: TARGATT™ CHO cell system for antibody screening and bioproduction/TARGATT™ HEK293 cell system for library/antibody screening • Animal Models: Custom and off-the-shelf CRISPR & TARGATT™ mouse models For patent licensing, business development, and investment inquiries, please contact us at info@appliedstemcell.com.

Fremont, California, United States

With APstem Therapeutics’ breakthrough discovery of Adult Pluripotent Stem Cells (APSCs™), we are on a mission to eradicate difficult-to-heal diseases and conquer the challenges of aging.

Irving, Texas

We are a clinical-stage biotech company dedicated to the discovery, development, and commercialization of advanced therapeutics that leverage the biological properties of human perinatal tissues and cells. All our efforts are made to support patients and help fulfill their unmet clinical needs.

Athens, Georgia, United States

Aruna Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body’s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders. We are leveraging our proprietary exosomes and manufacturing platform to create synergistic therapies by enhancing our exosomes with small molecules, RNA, oligonucleotides and antibodies.

Vancouver, Canada

Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of currently incurable diseases. Aspect is creating these next generation cell therapies by applying its full-stack tissue therapeutic platform, which combines the company’s proprietary bioprinting technology, therapeutic cells, biomaterials, and computational design. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body with the aim of treating currently incurable diseases such as type 1 diabetes as well as genetic and acquired liver diseases.

La Jolla, CA

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s disease (PD) and extending across the brain and affected organs.

Boston, Massachusetts, United States

Asymmetrex® is a life sciences biotechnology company with a focus on innovating adult stem cell medicine technology that will advance the potential of adult tissue stem cells into routine medical practice.

Institute Of Genetic Medicine Newcastle University, International Centre For Life Central Parkway, Newcastle upon Tyne, England, GB, NE1 3BZ

Crafting shelf-stable science inspired by hedgehogs, Atelerix is the answer to the cryopreservation headache. With a gel that's not just cool but doesn't need to be cold, they're setting cells, tissues, and viruses free from the icy grip of traditional storage and shipping methods. Welcome to the future of bioscience, where the storage is easy, and the cells are always fresh.

Cleveland, Ohio, United States of America

Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.

Maria Enzersdorf, Austria

Austrianova encapsulates living cells in tiny cellulose beads. The beads act as a microenvironment for living cells, allowing them to be metabolically active and divide, whilst being protected from the environment both in vivo (immunoprotection) and in vitro (sheer force, freezing stress protection). Cell-in-a-Box® enables allogenic or xenogenic mammalian cells to be protected from rejection by the immune system, but their porous nature allows therapeutic bioproducts to be released and encapsulated cells to survive for long periods. Cell-in-a-Box® has many advantages e.g. 1) clinically proven safety and efficacy upon implantation of encapsulated cells in patients 2) cells can grow within the capsules in bioreactors and are thus protected from shear forces - especially useful for fragile cells such as stem cells 3) freezing and storage of encapsulated mammalian cells at -80C for more than 5 years and then revival with greater than 90% viability, thus cells can be easily transported on dry ice. Bac-in-a-Box® enables probiotic bacteria and yeast to be encapsulated to protect them from harsh environments. Bac-in-a-Box® has a number of advantages e.g. 1) it is based on a natural polymer which is digestible 2) it totally protects probiotics from low pH as found in the stomach for extended periods (hours), allowing almost 100% of ingested probiotic cells to reach and be released in the lower intestine 3) it allows freeze drying of probiotics without appreciable loss of viability so they can be easily stored and transported at room temperature. We offer cell encapsulation R&D and cGMP production for both - mammalian cells (stem cells, engineered cell lines etc) all the way from the lab to clinical trial material (Cell-in-a-Box®) and for - bacteria and yeast encapsulation for excellent long term storage at ambient temperatures as well as 5 to 7 logs better protection from acid degradation in the stomach and later release in the large intestine (Bac-in-a-Box®).

Kildare, Ireland

Avectas is accelerating the future of cell therapy with a flexible, easy-to-integrate delivery platform that manufactures healthier and more functional cells for patients. Excelling at complex editing and challenging cargo delivery, the Avectas non-viral delivery platform ensures the next generation of cell therapies can be realized. The Solupore non-viral delivery system enables the next generation of cell therapies through unparalleled cell health and superior cell functionality, expanding the possibilities for complex editing and challenging cargo delivery. Easy to integrate into existing GMP processes, Solupore accelerates the translation of life-saving therapies to patients.

Atlanta, Georgia, United States

AventaCell BioMedical Co., Ltd. ("AventaCell") is among the world leaders devoted to developing novel human-derived products for use in cell culture and tissue regeneration. Helios Bioscience is AventaCell's product family brand for their products to be used in cell culture and tissue regeneration. AventaCell technologies used in the Helios Bioscience line offer new human-derived solutions for use in translational research of cell and tissue-based therapies to meet the need for animal serum-free cell expansion and production. The demand for safe, efficient and cost-effective cell expansion and production is rapidly increasing with the growth in cell therapy and regenerative medicine research and clinical development. Helios Bioscience products are designed to support expansion and production of a broad range of cells including mesenchymal stem cells and multiple immunocell lines. AventaCell is committed to providing animal serum-free products to accelerate the research, development and commercialization of safe and efficacious cell and tissue-based therapeutics.

Seattle, Washington, United States

AVM is a clinical-stage biotech company located in Seattle WA led by Dr. Theresa Deisher, a biotech veteran with a productive history including 47 patents and 4 discoveries in clinical trials. The company's lead drug AVM0703, an innovative formulation of dexamethasone, when given at suprapharmacologic doses has a novel mechanism of action to mobilize the body's own natural supercharged immune cells. AVM0703 triggers the production and release of endogenous gamma delta+ Natural Killer T cells and could be the first choice for no-option cancer, autoimmunity, and infectious disease. AVM Biotechnology has a Scientific Advisory Board including well-respected leaders in cancer and immunology. The company is committed to developing products that improve outcomes without additional suffering because side effects from treatments should never be worse than the diseases themselves.

Cambridge, United Kingdom

World leaders in iPSC technology supporting the next generation of advanced models for drug discovery We provide biopharma and virtual organizations with human iPSC-derived cells and outsourced laboratory services to support drug discovery in the neurodegenerative, neuroinflammatory, and cardiotoxicity areas. As leaders in human induced pluripotent stem cell (iPSC) products and services, we support the pursuit of more human-relevant in vitro models to develop better, safer therapies. We have over a decade of experience supplying top ten Biopharma institutions and drug discovery companies with robust, high-quality in vitro models and custom lab services. Our industry-leading iPSC capabilities support the pursuit of advanced in vitro disease models and supply volume for organ-on-a-chip devices and microfluidics platforms. From simple monoculture models to complex co- and tri-culture and 3D models, we continue to pioneer the advanced utility of iPSCs for research and drug discovery.

Seoul, South Korea

bBHC Stem Cell Treatment & Research Institute discovered the newly Elicited pluripotent Stem Cell without side effects which is called nEPS. We've been differentiated nEPS into endoderm,mesoderm and ectoderm. Our goal is overcome to incurable diseas using in nEPS.

海淀区永嘉北路4号院一号楼 中关村科学城星谷, Beijing, CN

BeiCell Therapeutics is a revolutionary cell therapy company stemming from Prof. Hongkui Deng's lab at Peking University, aiming to provide completely off-the-shelf cell therapy for cancer, autoimmune diseases treatment and regenerative medicine.

Plano, Texas, United States

Bimini Health Tech houses a diversified range of medical devices and regenerative therapies, with a portfolio that includes Puregraft®, Healeon®, Dermapose® and Kerastem®. The company develops and commercializes innovative products that are elegant in their simplicity, yet impactful and proven in their aesthetic, reconstructive and therapeutic benefit. Founded in 2013, Bimini has been providing targeted bio-therapeutic solutions in aesthetic and regenerative medicine.Bimini Health Tech is headquartered in Plano, TX with sales and distribution worldwide.

Newark, New Jersey, United States

BioCentriq is a premier contract development and manufacturing organization (CDMO) dedicated to advancing cell therapy. Since 2019, the company has specialized in GMP autologous and allogeneic cell therapies, offering end-to-end clinical-to-commercial capable services tailored to clients’ unique needs. Operating from two state-of-the-art U.S.-based facilities, BioCentriq provides a comprehensive range of services, including technology transfer and new technology evaluations, process and analytical development, cGMP manufacturing, quality control lot release, and stability studies. The company’s expertise spans diverse cell therapy modalities, such as T-cell (CAR-T, TCR), NK-cell, iPSC, and MSC-based products. With its proprietary LEAP™ manufacturing platform, BioCentriq accelerates service timelines while offering standardized and customizable solutions, including traditional fee-for-service, hybrid and person-in-plant operations, dedicated cleanroom capacity, and flexible service and contract arrangements. In addition to its technical capabilities, BioCentriq operates the Cell and Gene Therapy Experiential Learning Center, a training facility which provides hands-on and virtual instruction under the guidance of industry-experienced instructors and subject matter experts. The program has trained hundreds of participants, hosted major pharmaceutical companies, and integrates next-generation technologies and concepts into its curriculum including: Industry 4.0 and Lean principles, predictive analytics, augmented reality, and electronic batch record systems. Backed by GC Corporation, a South Korea-based leader in the healthcare, pharmaceutical and biotechnology industry, BioCentriq combines global expertise with a flexible working relationship, set to empower clients to develop and deliver cutting-edge, personalized therapies with unmatched precision and efficiency.

Netanya, Israel

BioGenCell was founded with the vision of developing safe, effective, and long-lasting effective treatment for incurable, blood vessel diseases that will be both accessible and patient friendly. Our disruptive TRACT technology platform provides a comprehensive approach for rapid manufacturing and commercialization of cell-therapies.

New Delhi, India

Later part of the bygone twentieth century has witnessed a major revolution in the field of life-sciences. Researches carried out during this period, particularly in the area of molecular biology and recombinant technology, have led to emergence of 'Biotechnology'​ with a new face. Plants, animals and microorganisms being a key component of our ecosystem have always remained at centre-stage of research for different purposes as they affect the human life. Development of culture methods, better understanding about molecular biology, discovery of restriction endonucleases and their use in mapping of DNA laid the foundation stone for modern day biotechnology. Isolation of thermostable DNA polymerase along with the development of PCR technique made cloning simplified and providing way for rec-DNA technology. Further developments were generation of bar-code like DNA fragment patterns of genomic DNA. These patterns appeared useful in distinguishing individuals based on DNA sequence variations among them. Such variations of DNA among organisms were termed as fingerprints or profiles which provide a versatile tool to characterize genetic variability, genome evolution, population genetics, taxonomy, breeding and diagnostics even today! The technology to read the DNA base-by-base made it possible to identify useful genes. This information which could be cloned in suitable vectors and introduced in appropriate hosts through a variety of gene transfer methods gave an impetus to genetic improvement programmes and production of Genetically modified organisms. Today the genomic sequencing is contributing to identify the basis of pathology, providing tailored therapies. We are quickly advancing towards the in situ engineering of the genomic information to achieve designer humanity. Bioheaven ventures into this space "Turning Human Needs into Careful Solutions"​..........

Prague

Production of therapeutically acting cell lines (somatocellular therapy) under the GMP regulations, FDF - final dosage forms, project management and development in GMP. Currently running and/or preparing multiple clinical trials with mesenchymal stem cells. Contractual manufacturing GMP. Czech biotechnology company primarily dedicated to research and development of novel stem cell-based therapies

Rehovot, Israel

Biokine Therapeutics is a private biopharmaceutical company founded in 2000. Biokine lead product BKT140/BL8040, is a high affinity, long-acting CXCR4 receptor inhibitor that already passed successful Phase III for Stem Cell Mobilization and Phase I/II for Immunotherapy for cancer together with immune check point inhibitor Pembrolizumab (Keytruda, Merck) and Atezolizumab (Tecentriq, Genentech/Roche). BL8040 was licensed to BiolineRx and is being developed in the clinic together with BiolineRx Ltd. (NASDAQ:BLRX). Biokine has also developed a suite of unique technologies, MigHit™ – which is a phenotypic screen that allows identification of small molecules targeting migration and survival pathways in cancer and ImmunHit™ which is platform technology enables identification of small molecules targeting IFN-g mediated immune response in cancer and inflammation.

Löfströms Allé 5, Sundbyberg, 17266, SE

BioLamina is a Swedish biotechnology company with a global presence, offering cell culture matrices for primary cells. We offer an expansive portfolio of recombinant laminin proteins for a variety of applications, including the reliable expansion of pluripotent cell and differentiation and maintenance of specialized cell types. Our chemically defined and xeno-free laminin cell culture matrices allow you to imitate the natural cell-matrix interaction in vitro. Laminins are key components of the extracellular matrix. Through their interactions with specific receptors, laminins trigger the authentic cellular responses, pivotal for cell anchorage, survival, proliferation, migration, organization, and specialization, leading to improved cell functionality. BioLamina's laminins are the only original full length, human, recombinant laminins on the market. Our high technology products contribute to our customer's efficiency and scientific breakthroughs and enable them to start a new era in medical research. We are known and recognized for our premium products, competence, dedication, and service and position ourselves as being in the forefront of cell culturing. Our vision is to make BioLamina a leading brand within the field of cell culture and to help make cell therapy a reality. BioLamina is built on a scientific foundation with a legacy in matrix biology and solid experience in cell culture-based research. The company was started in 2009 and was co-founded by Dr. Karl Tryggvason and his son Dr. Kristian Tryggvason. Today the company has about 35 employees spanning from production, R&D, logistics, sales, and marketing. Our quality system complies with ISO 9001:2015 and both management and employees follow well-defined standard processes and agreements.

San Diego, California, United States

BioLegend develops antibodies and reagents for biomedical research, manufactured in our state-of-the-art facility in San Diego, CA.

Buffalo Grove, IL

Pioneered by accomplished business leaders, guided by world-class biomedical and life science experts, and financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death worldwide. Leveraging advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation, this biotech company is committed to optimizing the process and technology around viable human organ replacement, and making it a safe, accessible, commercially viable, and cost-effective reality.

Jerusalem, Israel

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modi'in, Israel.

Worcester, Massachusetts, United States

BioPAL is a biotechnology company that provides novel diagnostic tools to the life science community.

Melville, New York

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. • Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Roma, Italy

Bioscience Institute is a cell factory dedicated to biological cryopreservation, cell culture and scientific research. The Bioscience Institute laboratories engage in the extraction, analysis, expansion and planned freezing of several cell types. The cryopreservation room, on the other hand, is used for storage of the stem cells extracted from the blood in the umbilical cord, from the adipose tissue and mature cells such as fibroblasts, melanocytes and keratinocytes. in collaboration with prestigious Italian and foreign universities, Bioscience Institute deals with scientific research work whose aim is to extend the possible clinical applications of stem cells to various areas of medicine: cardiology, surgery, neurology, gynaecology and dermatology.

Holliston, Massachusetts, United States

Biostage is a biotechnology company that focuses on developing organ replacement therapies using cellular scaffolds and tissue engineering.

Dresden, Germany

BIOTYPE is an innovative German solution provider for molecular precision diagnostics. We are committed to advancing precision medicine through our products & services for reliable analysis and interpretation of clinical biomarkers. BIOTYPE offers a strong portfolio in molecular cancer diagnostics for applications in hemato-oncology, liquid biopsy, and molecular profiling of solid tumors. The portfolio includes IVD assays for clinical diagnostics and RUO assays for translational and clinical research. In addition, BIOTYPE offers high-quality and IVD-compliant contract development and manufacturing services. Our proprietary MODAPLEX platform is a benchtop system for automated molecular profiling and multi-biomarker testing. MODAPLEX addresses the growing need to simplify and accelerate precision testing by reliably delivering actionable molecular information required for biomarker-guided care in precision medicine. The MODAPLEX consolidates multi-gene testing into one workflow with same-day results. BIOTYPE‘s quality management system is certified according to ISO 9001:2015 & ISO 13485:2016.

The Dorothy Hodgkin Building, Babraham Research Campus, Cambridge, Cambridgeshire CB22 3FH, GB

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey. For more information on bit.bio's trademarks, visit www.bit.bio/trademarks

921 Terry Avenue, Seattle, Washington 98104, US

Bloodworks Northwest is an independent, community-based nonprofit organization with a tradition blending volunteerism, medical science, education and research to advance transfusion medicine and improve patient care. A recognized leader in transfusion medicine, Bloodworks serves patients in nearly 90 hospitals and clinics in the Pacific Northwest and provides tissue and transplantation support to 185 hospitals across the Northwest. Patients with leukemia, cancer, burns, hemophilia and traumatic injuries also depend on Bloodworks research. With your help, we're bettering our community drop by drop.

Somerville, Massachusetts, United States of America

bluebird bio, Inc., a biotechnology company, engages in researching, developing, and commercializing of transformative gene therapies for severe genetic diseases and cancer. Its gene therapy programs include LentiGlobin for the treatment of ß-thalassemia and sickle cell disease; and Lenti-D for the treatment of cerebral adrenoleukodystrophy. The company’s product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Bristol-Myers Squibb to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; Forty Seven, Inc. to pursue clinical proof-of-concept for an antibody-based conditioning regimen; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases, as well as clinical trial collaboration with Magenta Therapeutics. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

Cambridge, Massachusetts, United States

BlueRock Therapeutics is a leading engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications. BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock’s culture is defined by scientific innovation, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit. The company strives to be a top employer of scientific talent, empowering every member of the team to make meaningful and lasting contributions to the burgeoning field of regenerative medicine. Become a BlueRocker! We are expanding our BlueRock team at all locations. Contact us via LinkedIn or our website to learn about rewarding career opportunities.

Pittsburgh, Pennsylvania, United States

BlueSphere Bio was founded to unlock the potential of personalized T cell therapy for the treatment of cancer by harnessing the unique specificity of each patient’s own T cells for the particular molecular fingerprint of each patient’s own cancer through our novel TCXpress technology. Our proprietary TCXpress platform is an elegant, rapid approach that exploits the patient’s own immune defenses to attack their cancer specifically, and is designed to leave normal tissues untouched, thereby reducing harmful side effects. The platform and implementation allows us to deliver rapid, personalized T cell treatments for a variety of cancer indications.

Providence, Rhode Island, United States

Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.

Copenhagen, Hovedstaden, Denmark

BOOST Pharma is based on years of collaborative research from Karolinska Institute in Stockholm with the focus on novel cell therapy treatments for Osteogenesis Imperfecta. The research teams of associate professor Cecilia Götherström and professor Magnus Westgren have shown that that treatment with BOOST Cells greatly enhanced the quality of life for patients suffering from this otherwise extremely debilitating disease.

New York, New York, United States of America

BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinson’s disease. These diseases have limited treatment options and represent unmet medical needs. NurOwn® is BrainStorm’s proprietary process for differentiating autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, transplanted at or near the affected tissue site. Our technology converts MSCs into a living drug delivery system for NTFs. We have proof-of-concept in various animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury. We have completed two single-arm clinical trials in ALS patients in Israel, demonstrating good safety and tolerability profiles and strong efficacy signals. We also finalized a Phase 3 randomized, double-blind, placebo-controlled clinical trial at multiple US sites, supported by a $16 million USD grant from the California Institute for Regenerative Medicine (CIRM) and another grant from the ALS Association. Currently, we are planning a Phase 3b clinical trial of NurOwn® in ALS under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). For more information, visit www.brainstorm-cell.com

9F, 9, Beobwon-ro 8-gil, Songpa-gu, Seoul, 05855, Republic of Korea

Founded in 2019, Brexogen is at the forefront of biotechnological innovation, dedicated to transforming the treatment of incurable diseases through our proprietary BG-Platform technology. As a pioneering bioventure, we specialize in the development of cell-free therapies, leveraging the untapped potential of stem cell derived exosomes. Our mission intertwines groundbreaking research with practical healthcare solutions. As we gear up for global expansion, our strategy emphasizes understanding local markets, forging strategic partnerships, continuous innovation, and engaging with the medical community to promote the benefits of exosome therapy. Rooted in South Korea, Brexogen is on a trajectory to enhance healthcare outcomes worldwide. We're dedicated to leading the charge in biotechnological innovation, offering accessible, effective treatments on a global scale. Join our journey as we strive for a healthier future across communities globally.

Fukuoka, Japan

A public biopharmaceutical company focused on developing novel cancer immunotherapies.

Taipei City, Taiwan

BRIM is a clinical-stage company developing novel peptide treatments for hard-to-treat diseases. BRIM’s first-in-class assets are based on its innovative stem cell regenerative PDSP technology platform, which has the potential to be effective in multiple therapy areas and indications.

San Diego, California, United States

Calidi Biotherapeutics is a clinical-stage biopharmaceutical company revolutionizing oncolytic viral therapies with stem cell-based platforms.

Roslin Innovation Centre, Easter Bush Campus, Midlothian

Carcinotech provides comprehensive solid tumour research services to therapeutic developers and healthcare professionals. At the heart of its offerings is the proprietary Carcino3D™ bioprinting platform, which creates assay-ready, 3D tumours from patient biopsies. Unlike conventional cancer models, Carcinotech’s bioprinted constructs incorporate multiple cell types—including immune cell populations—within a robust tissue matrix, offering a more biologically relevant and controlled model for early drug discovery, preclinical and co-clinical studies, and personalised treatment testing.

Mawson Lakes, South Australia

Carina Biotech An Australian clinical stage immunotherapy company established to research and develop chimeric antigen receptor T cell (CAR-T) therapies to treat solid cancers. Carina are working towards producing broad-spectrum CAR-T therapies that can be used to treat multiple solid cancers yet are patient-specific and result in little, if any, off-cancer damage. Using its proprietary platforms, Carina is also developing technologies to improve access to, and infiltration of, solid cancers, and to enhance CAR-T cell manufacturing. We are working to… 1. Expand the clinical indications for T cell therapies 2. Improve the commercial viability of T cell therapies by developing supporting technologies that make T cell therapies more effective or economically viable Headquartered in Adelaide, South Australia, Carina has strong T cell R&D capability across a network of research providers and collaborators including leading scientists at the UniSA, the Women's & Children's Hospital in Adelaide, the University of Adelaide, the Royal Prince Alfred Hospital in NSW and the Seattle Children's Hospital in the United States.

Notting Hill, Victoria, Australia

Cartherics works to create precisely-defined immunotherapy treatments to combat a variety of cancers. We take a multi-platform approach combining the best components of immune defences utilising gene editing and CAR technology. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Kefar Sava, Israel

CartiHeal, a privately-held medical device company with headquarters in Israel, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints. CartiHeal’s cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C has been implanted in over 400 patients with cartilage lesions in the knee, ankle and great toe in a series of trials conducted in leading centers in Europe and Israel. In these trials, the implant was used to treat a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in patients suffering from osteoarthritis. In the United States the Agili-C implant is not available for sale - it is an investigational device limited for use in the IDE study.

16700 Gulf Blvd, North Redington Beach, FL 33708, United States

We are an ISO 13485:2016 Certified Manufacturer developing innovative media formulations for cell cryopreservation, cell culture, and cell handling in cell therapy, gene therapy, and regenerative medicine. We deliver high-quality products with batch-to-batch consistency and rigorous quality controls from raw materials to final product release. We offer manufacturing services, scientific assistance in media formulation, and optimization of existing formulations to meet your specific needs.

8700 beverly boulevard, west hollywood, california, united states

• The Cedars-Sinai Biomanufacturing Center (CBC) is a new 25,000 square feet, state-of-the-art biomanufacturing facility located in West Hollywood, California. • Manufacturing the next generation of cell and gene therapies for human IND-enabling clinical trials. • cGMP cell manufacturing facility housing multiple cleanroom cell production suites and process development laboratories. • Combined expertise in a cGMP-compliant approach to manufacture cells at scale with innovative technologies and equipment. • Transferring laboratory protocols to cGMP, up-scaling of processes and achieving Food and Drug Administration standards to bring innovative cell therapy solutions to researchers and translational scientists. • World-class expertise in stem cell (iPSC) biology, gene editing and bioprocessing. • Supporting California Institute for Regenerative Medicine (CIRMN) programs, CBC is providing a much-needed cell biomanufacturing center in California

Utokyo Entrepreneur Lab., South Clinical Research Bldg., 7-3-1 Hongo, Bunkyo-ku, Tokyo. 113-8485

Celaid Therapeutics is a Japan-based biotechnology company, which has developed a platform technology to efficiently expand hematopoietic stem cells ex vivo without choosing its origins, including bone marrow, cord blood, or peripheral blood. By using the novel technology, we are developing a cell therapy product that brings HSC transplantation to the next level and helps patients with blood disorders. Our technology has many potential applications including gene/cell therapy that utilize gene editing on HSC. Our mission is to improve QOL of patients, their families, and HSC donors all over the world.

Manassas, Virginia, US

Celetrix is the leader in electroporation with our new high efficiency electroporation technologies for delivering DNA, RNA and proteins to cells. Celetrix provides technology and support for CAR-T manufacturing by transposon mediated expression and RNP mediated gene editing for T cells, stem cells and CD34+ HSC.

121 George Street, Glasgow, Glasgow G1 1RD, GB

The Offshore Renewable Energy (ORE) Catapult forms part of an elite network of eight technology and innovation centres established and overseen by Innovate UK, which represents a £1bn public and private sector investment over the next five years. ORE Catapult is the UK's flagship technology innovation and research centre for offshore wind, wave and tidal energy. We deliver prioritised research underpinned by world-class test and demonstration facilities, collaborating with industry, academia and Government to reduce the cost of offshore renewable energy and create UK economic benefit.

San Diego, California, United States

Global Leadership in Primary Cells: Excellence in cell isolation, 3D bioprinting, tissue engineering, 3D cell models, stem cells, optimized culture media and more. CAI's products and custom services support basic life science research and biopharmaceutical drug discovery. Our Center for Primary Cell Innovation pushes the edges of technology, with regular advancements developed in collaboration with academic & industry experts.

Boston, Massachusetts, United States

About Us: Cell BioEngines, Inc., founded in Dec 2022, is a clinical-stage biotech company focused on developing allogeneic 'off-the-shelf' stem cell and its derived therapies as ‘drugs’ for human disease treatment. The company utilizes a ‘plug-and-play’ proprietary platform technology that transforms universal ‘non-gene-modified’ donor blood stem cells from umbilical cords, to produce high-quality, pure and potent, multiple clinical grade cells at scale. This innovative method aims to make stem cells and its derived therapies more accessible and efficient. Its lead product is currently in Phase 1 trials for the treatment of hematopoetiic neoplasms not curable with available therapies, particularly acute leukemia and myelodysplasia. The lead pre-clinical stage product is a first-in- class ‘one-size-fits-all’ cell-based cancer vaccine, composed of dendritic cell type 1 (cDC1) to circumvent the barriers in solid cancers. Platform Technology: The company's platform technology is what makes it innovative and unique. It's "Cell BioEngineMAP" is a cutting-edge platform for developing multiple cell therapy assets, leveraging the remarkable potential of universal umbilical cord-derived blood stem cells. These cells serve as a foundational source, which we can expand, differentiate, and de-differentiate using our proprietary chemical reprogramming methods to produce pure, powerful rare cell states, at large scale for clinical applications. Complementing this, our "Cell BioEngineAI" platform employs artificial intelligence to predict donor availability and target characteristics, ensuring the safety and efficacy of HLA-compatible therapies. Our goal is to create a ready-to-use, 'off-the-shelf' cell bank with therapeutic products that cover over 85% of the population, available at selected blood centers. For more information, visit www.cellbioengines.com and follow us on www.twitter.com/cell_bioengines

San Diego, California, United States

Cell Biolabs, Inc. proudly develops and commercializes innovative technologies and tools for life science research. We are committed to providing the best products that facilitate discovery of the mechanisms underlying cell function and disease. Our unique, cutting-edge products are currently used around the world in the research laboratories of universities, government institutes, biotechnology and pharmaceutical companies

Chennai, IN

Basel, Basel-Stadt, Switzerland

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD)

Freiburg, Germany

Sartorius CellGenix is a leading global supplier of high quality raw and ancillary materials for the expanding market of cell and gene therapy and regenerative medicine. We develop, manufacture and market human cytokines, growth factors, and other recombinant cell culture components in preclinical and GMP quality as well as prorietary serum-free media for further manufacturing of ATMPs. Our products are used by academia and industry partners in clinical trials and commercial manufacturing throughout the world. As an ATMP developer and manufacturer we gained in-depth cell culture knowledge and superior regulatory expertise. With this unique background we understand the high requirements our customers face during product development and the regulatory approval process. Sartorius CellGenix is headquartered in Freiburg, Germany.

Cambridge, Massachusetts

Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.

510 Charmany Drive, Suite 254, Madison, Wisconsin 53719, US

Cell Line Genetics, Inc,(CLG) is the leading independent provider of multi-species Quality Assurance services and products for the Regenerative Medicine market. Headquartered in Madison, Wisconsin and with offices in New York City, CLG's clients include leading universities and research institutes, as well as biotechnology and pharmaceutical companies. For a complete list of CLG products and services please visit www.clgenetics.com.

Halethorpe, Maryland, United States

Cellomics Technology, LLC is dedicated in developing more efficient and powerful tools to enhance and accelerate life science researches. Top scientific excellence is the goal and focus of our scientists.

Hangzhou, Zhejiang

CellOrigin Biotech has a long term focus on iPSC-derived innate immune cells and its applications in new cancer immune cells. Dr. Jin Zhang, the scientific co-founder of CellOrigin used to be trained as a research fellow at the Boston Children’s Hospital and Harvard Medical School. His team worked closely with clinicians at the First Affiliated Hospital of Zhejiang University and for the first time reported the induced pluripotent stem cell or iPSC-derived CAR-macrophages (CAR-iMac), and its applications in cancer immunotherapies. As for now, CellOrigin Biotech holds its proprietary technologies for iPSC-derived CAR-Macrophage. With this platform, they are collaborating with research groups in genome engineering and synthetic biology at Harvard and MIT to fully unleash the potential of iPSC-derived immune cells, which are highly editable, expandable and clonal. Eventually, they would like to achieve a goal of bring more effective, universal and safe immune cell products to cancer patients, especially for those with solid tumors. The investigator initiated trials has been initiated at the First Hospital of Zhejiang University. The core proprietary technology platform and the core patents including the engineered macrophages from pluripotent stem cells has been authorized and is in the process of entering the US, Australia, South Africa, etc.

Mulhouse, France

CellProthera, a biotechnological company, has developed a unique therapeutic technique which enables the structural and functional regeneration of severe post-infarctus cardiac lesions. After European and national (FR/GB) authorization was obtained , CellProthera has started its I/IIB clinical trial in Humans.

Singapore, Singapore

CellResearch Corporation was founded in Singapore in 2002 by scientists with a keen interest and expertise in Cell Biology. In 2004, our scientists isolated Epithelial and Mesenchymal Stem Cells from the Umbilical Cord Lining Membrane. This novel and significant discovery was put up for intellectual property protection, and to date we have patents granted in multiple strategic key territories around the world. The umbilical cord lining membrane is now known to be the richest source of stem cells in the body, and both epithelial and mesenchymal stem cells are being researched intensively with collaborators all around the world to exploit their potential for downstream medical therapy. Considerable headway has already been achieved, and we have started USFDA Clinical Trials with our collaborators in the USA, leading to a therapy to accelerate wound healing.

Las Condes, Región Metropolitana de Santiago

Cells for Cells S.A. is a Chilean-based biotech company dedicated to the research, development and commercialization of cell therapies and tissue-engineered revolutionary solutions. The company counts with a broad portfolio of more than 10 technologies including Cellistem®OA, a clinical trial-supported cell therapy for the treatment of knee osteoarthritis, Inkure®, a bioink for the treatment of focal chondral lesions, Oxium®Exo, a culture media for the production of exosomes, and Veintis™, a bioinspired tissue-engineered vascular graft for vascular bypass applications, among others. Cells for Cells S.A. (a.k.a. C4C) is a spin off from Universidad de los Andes, Chile, and was founded in 2010.

Houston, Texas, United States

Celltex Therapeutics Corporation is a Houston, Texas-based biotechnology company focused on spearheading breakthroughs in regenerative medicine using adult, autologous Mesenchymal Stem Cells (MSCs).

Chuo-ku, Tokyo, Japan

Cellusion is committed to pursuing a patient-centric approach at our cutting-edge research and development (R&D) for diseases where regenerative medicine technologies can create a unique value proposition. We expand the possibilities of people around the world both physically and mentally.

40 Berkeley Square, Bristol, England BS8 1HP, GB

CellVoyant is an AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases. Our technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale. CellVoyant is built on foundational work from the Carazo Salas lab at the University of Bristol. We're working at the exciting intersection of cell biology, computer vision, engineering, and machine learning to industrialise next-generation science from research into the real world. Our mission is bold and ambitious and we have the best investors behind us from day 1. We're backed by venture capital firms who were the earliest investors in AI pioneer DeepMind, the two leading AI-first drug discovery companies, Exscientia and Recursion, and self-driving challenger Wayve. We're also supported by the founder/CEO of Abcam, which pioneered the antibody business.

Cleveland, Ohio, United States

Cell X is pioneering a revolution in cell processing. At the core of this revolution lies our transformative Celligent platform – an innovative bundling of automation, imaging, data analytics, and machine learning that enables therapeutic researchers to develop consistent, reproducible, and scalable GMP-compliant processes for stem cells and bio-fabrication. Celligent enables the development of safe and effective products by executing the necessary process development and cell manufacturing procedures in a fully documented, compliant way. Successful cellular therapies demand starting with optimized cell sources; and intrinsic variability and heterogeneity among cell sources presents a major challenge. This critical first step of control over starting materials demands the use of quantitative and reproducible standards for cell and clone selection and process management based on critical process parameters (CPPs) in order to achieve products with defined critical quality attributes (CQAs). Backed by a highly experienced team, Cell X automates cell processing in diverse cell culture applications spanning mesenchymal stromal/stem cells (MSCs) and exosomes, induced pluripotent stem cells (iPSCs), hematopoietic stem cells (HSCs), connective tissue progenitor cells (CTPs) and tumor-infiltrating lymphocytes (TILs) as well as other progenitor cell types. We are dedicated to advancing the promise of cellular therapies for innovators and patients alike, ultimately making cell therapies more accessible to millions of patients worldwide. 

406 World Trade Center, Sayajigunj, Vadodara, Gujarat 390005, IN

Century Pharmaceuticals Ltd is a privately held Pharmaceutical Company based out Vadodara, India. For more than 30 years, we have emerged as a respectable name in the industry. Our services include manufacturing APIs, facilities for contract manufacturing, Biotechnology research, API research, stability studies, and more.

Philadelphia, Pennsylvania, United States

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company’s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. Century Therapeutics, Inc. has a research collaboration with Outpace Bio, Inc. for CAR engineering. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

335 pangyoro bundanggu, seongnam, korea

CHA Bio Group is continuing its challenge to become the best in various initial achievements in the bio and healthcare fields. We are developing and producing advanced biopharmaceuticals, including cell and gene therapy products and vaccines, based on our global R&D capabilities, such as our unique ‘CHA Bio ecosystem': Academic, Research, Medical Network, and Bio-Industry Business, the world's largest cell library, and our independently developed vaccine adjuvant platform. We will leap forward as a true global bio company centered on the third-generation CGT CDMO and global healthcare business.

CHA Complex 335,Seongnam

CHA Biotech is the only company in Korea that has a collective eco-system integrating CHA Medical University, CHA Advanced Research Institute, and CHA Hospitals within the group collaborating to develop new drugs by conducting basic research and clinical trials up to commercialization. CHA Biotech has the world's largest cell library (embryonic and adult stem cells, immune cells) that can be applied to cure various diseases, and has differentiated technology including 88 globally registered patents for cell technology. Based on our R&D competency, the company develops cell and gene therapies for diseases that are unmet and are in high demand for cure such as cancer, incurable diseases, and aging-related diseases.

Galveston, Texas, United States

Chrysalis BioTherapeutics, Inc. is a privately held biopharmaceutical company developing regenerative drugs that mimic the body’s natural signals to activate endothelial progenitor cells and stem cells to stimulate tissue repair and restore normal tissue function. Chrysalis BioTherapeutics was incorporated in Delaware in 2012 to develop innovative peptide therapeutics to save lives and improve life’s quality. Chrysalis’ lead drug candidate, TP508, was initially developed to accelerate healing of dermal and musculoskeletal injuries. It proved to be especially effective in promoting healing of diabetic foot ulcers in early human clinical trials and is under development as a treatment for mass casualty injuries and burns. Chrysalis has demonstrated that TP508 mitigates effects of radiation exposure. Chrysalis is therefore collaborating with US government agencies to develop TP508 as a nuclear countermeasure to combat acute and delayed radiation syndromes and to mitigate damaging effects of brain cancer radiation therapy.

Basel, Basel-Stadt, Switzerland

Cimeio Therapeutics is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs for patients with serious and life-threatening diseases. Cimeio’s proprietary technology platform is based on the discovery of protein variants, which when edited into cells allow them to maintain full function while resisting paired immunotherapy depletion. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.

1 broadway, cambridge, massachusetts, united states

Cimeio Therapeutics is a biotechnology company based in Massachusetts, specializing in gene editing, cellular, and immunotherapy. The company focuses on developing Shielded-Cell & Immunotherapy Pairs (SCIP), which are innovative immunotherapies aimed at treating serious diseases such as genetic disorders, hematologic malignancies, and severe autoimmune conditions. Cimeio's proprietary technology platform enables the discovery of novel protein variants that help cells maintain their function while resisting depletion from targeted immunotherapies. Their core products combine modified cell surface proteins with immunotherapies, ensuring the preservation of healthy cells during treatment. Additionally, their Cell-Shielding Technology protects hematopoietic stem cells from immunotherapy-induced depletion, allowing for effective treatment of diseased cells. Cimeio has formed significant partnerships, including a collaboration with Kyowa Kirin to develop novel cell therapies and a research partnership with the University of Pennsylvania to enhance their immunotherapy research capabilities. The company has received recognition for its innovative approach, with features in publications like Forbes and research published in Nature.

Cleveland, Ohio, United States

One of the few FDA-licensed cord blood centers in the U.S., the Cleveland Cord Blood Center (CCBC) collects, processes, stores and distributes stem-cell rich umbilical cord blood for transplantation in patients with life-threatening disorders.

Oklahoma City, Oklahoma, United States

COARE Biotechnology is a multidisciplinary drug development company that seeks to advance the current treatment modality of patients with aggressive cancers by coordinately targeting aspects of both the primary tumor and the biological processes that effect metastatic initiation and progression. Our team has garnered worldwide acclaim for their groundbreaking scientific discoveries in support of the novel therapeutic platforms developed here at COARE Biotechnology. We have identified key components within cancer biology that have not been targeted – until now.

1401 lavaca street, austin, tx, united states

The science of genetics. The business of discovery. Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity's duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.

Berkeley, California, United States

Working on turning stem cells into human eggs

Paris, France

New technologies for protein design.

One Baylor Plaza, Houston

CoRegen is leveraging its groundbreaking master gene regulator platform to develop a broad range of therapeutics capable of controlling numerous genes throughout the body, with lead indications in solid tumors.

Seongnam-si, Gyeonggi-do

CorestemChemon is a global biotechnology corporation centered on stem cell-based new drug development and non-clinical research divisions. Motivated by the urgent need for medication for patients, the bio-pharmaceuticals division remains dedicated to research and development. In 2014, the unit successfully commercialized Neuronata-R inj, a stem cell therapy for the rare disease Amyotrophic Lateral Sclerosis (ALS), making it the fifth stem cell therapy approved for use globally. Alongside ALS treatment, the division has pipelines for various diseases such as lupus, Neuromyelitis Optica (NMO), and multiple system atrophy (MSA). Leveraging the success of the ALS stem cell therapy, the unit plans to concentrate on developing treatments for rare and incurable neurological and autoimmune diseases to dominate new market.

Shirley, New York, United States

Creative Bioarray uniquely pioneers the development of high quality tissue, antibody, protein and cell array technology to efficiently analyze the concurrent expression and function of proteins involved in inflammation, angiogenesis, apoptosis, cell growth, and signal transduction from a single biological sample. Creative Bioarray is a well-recognized service provider propelled by integrity, expertise and the desire to contribute to simplify, improve, and accelerate research speed of the scientists by providing the highest standard quality research products and services. Since it founded, Creative Bioarray had recognized that an important obstacle to make development of basic bioscience and preclinical researches using human specimens is the lack of access to reference materials. Consequently, Creative Bioarray was determined to be the first commercial entity specialized in building up the largest tissue-sharing platform by integrating the detailed clinical information of all the tissue samples.

Phoenix, Arizona, United States

Creative Medical Technology Holdings, Inc., formerly Jolley Marketing, Inc., is a clinical-stage company. The Company conducts its business operations primarily through its subsidiary, Creative Medical Technologies, Inc. (CMT). The Company is engaged in stem cell research and applications for use to treat male and female sexual dysfunction, infertility, miscarriages and related issues. CMT focuses on completing the testing of its erectile dysfunction (ED) treatment and, if warranted, marketing treatment kits under the name Caverstem to physicians for use with their patients suffering from ED. CMT also intends to test and, if warranted, market licensed stem cell products under its infertility technology license. Procedures for use of the Company's ED stem cell treatment consist of a one-hour out-patient visit in a physician's office. The physician would harvest a patient's bone marrow from the hip using local anesthetic and separate the stem cells using a cell separator.

Bengaluru, India

CrisprBits was started by entrepreneurs and scientists with extensive industry and academic experience, including in the biological sciences. We have prior experience in developing diagnostic solutions, precision medicine and clinical-research solutions that are used by pharmaceutical and biotechnology companies in India and around the world. We are motivated by three guiding principles: using deep science to deliver high quality products; adhering to the highest ethical standards, including in the choice of products we offer; and developing an organization that draws exceptional individuals with diverse backgrounds and affinities. We have offices in Delhi and Bengaluru. Our lab is located in C-CAMP, a premier incubator for biotechnology innovation in Bengaluru.

South Boston, Massachusetts, United States of America

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

ottawa, ontario, canada

CryoStasis is a biotech company specializing in bio-preservation of cells, tissues and organs. Located in Ottawa and based on 30 years of pioneering research in the Canadian Arctic, we have developed a method that overturns the long-held belief that biological material must be frozen for its function to be preserved. By using rationally designed cryoprotectants (Woolii™Cool media) along with temperature and pressure management systems (Woolii™Pod), our platform drops temperatures well below freezing, halting cellular metabolism WITHOUT TURNING WATER INTO ICE. Maintaining sub-zero, unfrozen conditions induces stasis (indefinite preservation) while avoiding the dramatic loss of cell function, therapeutic potency and manufacturing yield that occur as a result of freeze-thaw damage. CryoStasis works with BioPharma, CDMOs and research institutions to help ensure life-changing cell & gene therapies can be produced at-scale economically, and reach patients whenever / wherever they are needed.

Cambridge, United Kingdom

Seoul, Republic of Korea

Curamys is a biotechnology company that develops cell fusion technology to cure intractable diseases.

Seattle, Washington, US

Austin, Texas, United States

Curtana Pharmaceuticals is a privately-held, preclinical-stage biopharmaceutical company developing first-in-class, small molecule therapeutics that are highly specific for cancer stem cells in the central nervous system (CNS) for the treatment of glioblastoma (GBM) and other brain cancers.

Carlton, Victoria, Australia

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors. Cynata’s lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Clinical trials of Cymerus MSC products in osteoarthritis (Phase 3) and in severe complications arising from COVID-19 (Phase 2) are currently ongoing. Planning is also underway for further clinical trials of Cymerus MSC products in GvHD (through licensee Fujifilm), critical limb ischemia, idiopathic pulmonary fibrosis, renal transplantation, and diabetic foot ulcers. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of numerous diseases, including the clinical targets mentioned above, as well as asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Singapore

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s national research and development agency in the public sector. CytoMed is a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors.

38 Wareham St, Boston, Massachusetts 02118, US

CytoTronics is commercializing technology emerging from the Harvard University labs to bring unique insights to drug discovery. A revolutionary approach to studying cell biology, powered by microchips.

Aventura, Florida, United States

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive Flex-NK™ bispecific antibody and iPSC-derived, TALEN® gene-edited NK-cell platforms. FLEX-NK™ bispecific antibodies are built on a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology. The company is also developing three types of iPSC-derived NK (or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. ​ These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as relapsed multiple myeloma. Clinical studies are expected to initiate in 2023.

San Diego, California, United States

Our mission is to improve the way we grow cells for stem cell R&D and cultured meat production. We care about making a positive impact in reducing animal dependency for lab reagents and eventually for food as well. Defined Bio's journey starts with transforming stem cell growth medium by understanding the most critical stem cell research needs - cell growth quality, cost, and ease of use. To meet the growing demands of various customer segments, we realized that we would have to optimize all of the fundamental ingredients of defined, animal free growth media: growth factors, proteins, buffers, and growth/differentiation analysis. We have developed innovative reagents across traditional recipes, leveraging published and optimized recipes from leaders in the field. The result is exceptional reagents, media, and protocols that will materially improve quality and reduce the cost of growing stem cells and iPSC derived cells.

Cambridge, United Kingdom

DefiniGEN are a Cambridge UK company providing highly functionalhuman cell productsincludingliver, pancreas, lung,and intestinal cells pluscustom servicesfor drug discovery and disease model generation.

Cambridge, United Kingdom

Seattle, Washington, United States

Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.

Schlieren, Zurich, Switzerland

DiNAQOR is a genetic medicine platform company pioneering early-stage drug development and manufacturing to advance promising gene therapies to the clinic. Our patent-protected, industry leading platform is designed to overcome the challenges and limitations of advanced gene therapy development by using proprietary engineered heart tissue technology (EHT), a novel Loco-Regional Perfusion system (LRP) and a fully integrated manufacturing solution. Our company is headquartered in the Greater Zurich Area, Switzerland, with additional presence in Laguna Hills, California and Hamburg, Germany.

1-17-8 Shinkiba, Koto-ku, Tokyo 136-0082, Japan Mitsui Link Lab Shinkiba 2 Room 223

Dioseve Inc. Our revolutionary technology, DIO (Directly Induced Oocyte), is capable of producing an extremely large yield of fertilizable egg cells at a minimal cost.

Austin, TX, USA

Direct Biologics is a market-leading innovator in regenerative medicine.

Salt Lake City, Utah

DiscGenics is a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what we hope will be a profound therapeutic option for millions of patients suffering from the debilitating effects of back pain. DiscGenics’ first product candidate, IDCT, is a homologous, allogeneic, injectable cell therapy for the treatment of patients with mild to moderate degenerative disc disease.

Irvine, California, United States

Diagnostic testing for patients across all rare genetic diseases, including Cystic fibrosis, Fabry disease, Epilepsy, Hemophilia, all types of hereditary cancers, and cell and gene therapy.

Cambridge, Massachusetts, United States of America

At Editas Medicine, we are pioneering the possible. Our mission and commitment is to harness the power and potential of CRISPR gene editing to develop a robust pipeline of medicines for people living with serious diseases around the world. Our goal is to discover, develop, manufacture, and commercialize transformative, durable genomic medicines for many diseases.

Baltimore, Maryland, US

Elixirgen Scientific is a global leader in regenerative medicine and biotechnology, headquartered in the Science + Technology Park at the Johns Hopkins Medical Campus in Baltimore, MD. Our mission is to advance science and medicine with fast, functional, and scalable induced pluripotent stem cell (iPSC) differentiation products and services. Our state-of-the-art, transcription-factor-based technology allows you to overcome the high cost and inefficiencies associated with lengthy cell differentiation periods. We empower research institutions, pharmaceutical organizations, and biomedical enterprises worldwide, even those with no previous iPSC experience, by increasing access to relevant cells for modeling human biology and accelerating the path to drug discovery and development. This commitment to innovation and efficiency underpins our goal to revolutionize regenerative medicine. We are the partner of choice for supplying high-quality, reliable iPSC-derived cells and kits and conducting customized research services. Connect with Elixirgen Scientific today to discover how we can accelerate your research!

Baltimore, Maryland, United States

Elixirgen Therapeutics is a biotechnology company advancing its controllable self-replicating RNA technology to develop therapies for a broad spectrum of diseases, including rare diseases, aging-related disorders, and cancer. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore.

319 North Bernardo Avenue, Mountain View, CA 94043

Encellin is a biotechnology company specializing in cell encapsulation technology for cell-based therapeutics. The company's initial pipeline focuses on endocrine disorders with a clear mechanism of action, particularly focusing on Hypoglycemia. Encellin was founded based on the technology developed in the lab of Dr. Tejal Desai at the University of California in San Francisco.

Zurich, Switzerland

endogena’s mission is to discover and develop first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. our approach has the potential for a medical treatment paradigm change to effectively address unmet medical needs associated with ageing and genetic diseases. endogena therapeutics is implementing state-of-the art innovation in the field of regenerative medicine. our science combines the latest developments in stem cell biology, artificial intelligence and our expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases. recent breakthroughs in stem cell biology together with technological advances for phenotypic, functional screening have unlocked our ability to harness the potential of adult stem- and precursor cells. our novel drug discovery approach is based on the concept of selective activation of endogenous progenitor cells for controlled tissue repair and regeneration by small molecules.

Boston, Massachusetts, US

Milan, Lombardy, Italy

We develop first-in-class biologics for several underserved autoimmune conditions. Our therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases

760 Parkside Avenue, Brooklyn, New York 11226, US

EpiBone is a revolutionary bone reconstruction company that allows patients to "grow their own bone". EpiBone's pioneering technology utilizes a scan of the patient's bone defect and the patient's own stem cells to construct and cultivate a defect-specific autologous-like bone graft. EpiBone is strategically positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year.

Shanghai, China

Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases.

San Diego, California, United States

Epirium is a clinical-stage biopharmaceutical company that has developed unique insights related to the biology of mitochondrial biogenesis and tissue function, potentially resulting in novel therapeutic approaches to currently intractable neuromuscular diseases. The company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and tissue regeneration. Epirium is currently planning clinical trials with its initial drug candidate in Becker muscular dystrophy

Manchester, United Kingdom

Epistem Ltd. is a leading contract service provider offering innovative preclinical research services, genetic and protein biomarker testing as well as histology services to pharmaceutical, biotech and academic customers to support to drug discovery and development pipelines. We have worked with over 200 pharmaceutical and biotechnology companies at both preclinical and clinical stages. Our high level of expertise and customer focus has led to an enviable track record and impressive amount of repeat business. Our preclinical contract research services group advance drug development programs for oncology, inflammatory, dermatology, auto-immune and GI disease indications. We offer an impressive range of preclinical models in these therapeutic areas. We also provide information relating to toxicity assessments and are experts in GI tox. We also offer a broad range of cell based assays including novel stem cell assays. Our biomarker services division offers GCLP compliant genetic testing, histology, FACS analysis and protein biomarker detection. Epistem’s genetics group offer gene expression and DNA genotyping sample analysis by NGS, microarray and qPCR. We specialise in working with small starting materials (down to a single cell input) applying our proprietary low input techniques and products to support drug development programs. We are specialists in fractionating cell populations and conducting genetic analysis. We have pioneered techniques using plucked scalp hair and laser capture microdissected material to provide gene expression biomarker information to drug development programs. Epistem is committed to provide reliable and innovative services to support all phases of drug development from to preclinical projects to clinical trials. Website: www.epsitem.co.uk

Alachua, Florida, United States

EriVan Bio is a biotechnology company that focuses on innovating and delivering products and services related to exosome technology for molecular and cell biology research, regenerative medicine, and drug delivery.

Cambridge, Massachusetts, United States

Eterna Therapeutics is developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. We and our strategic partners are advancing innovative nucleic acid and cell therapies that offer the hope of radically improving the health outcomes of patients with high unmet medical needs. We are committed to creating a world in which patients and their families have access to effective, life-changing treatments for serious illnesses.

Austin, Texas, United States

Everlum Bio is pioneering a novel approach to drug development for rare diseases. As opposed to working on a single disease we are doing "Drug Development as a Service". We are relentlessly focused on innovating the drug development process. Ultimately we believe this approach will usher in a personalized/precision medicine revolution.

Hamburg, DE

Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.

Montreal, Quebec, Canada

ExCellThera is an advanced clinical-stage company specializing in cell expansion and engineering, providing molecules and bioengineering solutions to expand stem cells.

Epalinges, Switzerland

Exogems uses an FDA-approved medical device (Lipogems®) to produce exosomes from the mesenchymal stems cells in fat. They are developing methods for using these exosomes to deliver therapeutics.

Bhubaneswar, Odisha, India

EXSURE is an R & D-based startup and we are developing the next generation of exosome-based cancer therapeutics. We are developing a unique exosome-based chemotherapeutic drug-delivery platform that will facilitate precise and guided delivery of anti-cancer drugs (existing on the market) into tumor cells and relapse-causing cells (cancer stem cells) without abruptly harming the healthy cells. Our platform will reduce chemotoxicity and chances of cancer relapse in cancer patients. Currently, we are working with a breast cancer model. We have validated the efficiency and efficacy of our platform in vitro (in different breast cancer cell lines and derived cancer stem cells) and ex-vivo (primary cells & stem cells derived from chemo-naive clinical samples of breast tumor biopsies). We are yet to validate our platform in vivo (SCID mice). We have filed the patent for the formulation we are using to develop these bioengineered drug-loaded targeted exosomes and the methodology behind it (Final patent to be filed this month). We are providing outsourcing services including any type of cell-culture-based assays, exosome-based experimentations, and cancer stem cell-based assays.

Cambridge, Massachusetts, US

Factor Bioscience develops new technologies in a little-explored area that we believed had enormous potential: messenger RNA ("mRNA").

San Diego, California, United States of America

Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders.

Houston, Texas, United States

FibroBiologics is the world leader in cell therapy using fibroblasts to regenerate tissue and cure chronic diseases. Currently, FibroBiologics holds 150+ U.S. and international issued patents issued/pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, and Cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.

Milan, Michigan, US

Founded in 1990, Telethon Italy is one of the biggest biomedical charity in Italy, whose mission is to advance biomedical research towards the diagnosis, cure and prevention of muscular dystrophies and other human genetic diseases. Telethon Italy focuses on scientific research and does not offer healthcare, material assistance to patients and families or advocacy. Since 1991, Telethon Italy has invested 394 million Euros in research and funded 2,477 research projects on more than 445 human genetic diseases, which range from basic research to clinical trials.

New York, US

FOXG1 Research Foundation (FRF) is a US-based 501(c)(3) not-for-profit dedicated to accelerating research to find a cure FOXG1 syndrome. Previously called Brain Factor 1, FOXG1 is one of the first and most fundamental genes formed during brain development. Most children with FOXG1 syndrome cannot walk, talk, crawl, or take care of their most basic needs; most have a feeding tube, most undergo major surgeries, and most suffer from life-threatening seizures. Many leading neuroscientists believe that FOXG1 holds the key to unlocking many brain disorders that affect millions of people including autism, schizophrenia, Alzheimers and brain cancers. They also believe FRF can get to human clinical trials in three to five years. The FOXG1 Research Foundation was founded by FOXG1 moms in 2017 with the support of a worldwide team of FOXG1 parents. FRF is quickly becoming known in the biotech arena as a Patient Organization making tremendous strides. FRF raised more than one million dollars in less than one year and has successfully funded six major research projects fostering the most comprehensive study of FOXG1 to-date. The potential to improve millions of lives is tremendous. The time is now. Join us to pioneer some of the most ground-breaking research in human history. 1 www.foxg1research.org

Madison, WI

Fujifilm Cellular Dynamics, Inc. develops and manufactures biologically relevant human cells derived from induced pluripotent stem (iPS) cells. Our iCell® and donor-specific MyCell® Products are highly pure, highly reproducible, and available in industrial quantity to enable drug discovery, toxicity testing, stem cell banking, and cell therapy development.

San Francisco, California, United States

GABAeron, Inc. is a biopharmaceutical company focusing on the development of therapies using stem cells and small molecules to treat neurological diseases. GABAeron takes a novel approach that combines precision medicine (using genetic information for patient stratification) with regenerative medicine (using human iPSC-derived cell products for therapy) and pharmacological intervention (small molecules). The therapeutic programs of GABAeron are specifically designed to replace or protect some of the most vulnerable brain cell populations to restore and preserve brain functions with human iPSC-derived cell products and small molecules in patients with genetically defined neurological diseases.

New York, New York, United States

Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives. Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. We aim to change that. Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, we have developed a platform to produce female reproductive cell lines. We use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Our team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Our first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno.

Jerusalem, Israel

At Gamida Cell, we are striving to enable patients with blood cancers and serious blood disorders to reach cures through advanced cell therapy. We work with a sense of urgency and deeply held responsibility to address the clear need for new treatment options. And we believe that cell therapies should be available to patients who can benefit from them.

Cambridge, MA

Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 120 diseases. https://garudatx.com

cambridge, massachusetts, united states

GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church's lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.

San Diego, California, United States

Gene Biotherapeutics is a biotechnology company that focuses on the clinical development and commercialization of DNA-based biotherapeutics for the treatment of cardiovascular disease.

Norcross, Georgia, United States

GeneCure Biotechnologies is a biotechnology company that focuses on developing gene therapy based technologies to treat genetic and acquired human diseases.

Milan, Italy

Genenta (Nasdaq: GNTA) is a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors. Our platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro environment. Genenta’s lead product candidate, Temferon™, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance. Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.

Jerusalem, Israel

NeuroKaire by Genetika+ a personalized medical testing tool to better treat depression by helping physicians find the best drug therapy for their patients. NeuroKaire uses innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Seoul, Seoul-t'ukpyolsi, South Korea

Founded in 2016 in South Korea, Genuv(지뉴브) is a clinical-stage biopharma that specializes in discovering and developing innovative therapeutics based on own platform technologies for drug discovery. GENUV is dedicated to the discovery and development of life-transforming therapeutics for patients with debilitating diseases. To do this, we passionately endeavor to advance our own platform technologies and capitalize on our strengths in multi-disciplinary collaborations with external partners. Our current research and development focus is on a) small molecule drugs to treat neurodegenerative diseases through neurogenesis and neural homeostasis and b) antibody drugs for immuno-oncology treatment.

Boca Raton, Florida, US

Gift of Life Marrow Registry facilitates blood stem cell and marrow transplants for children and adults battling life-threatening diseases, including leukemia, lymphoma, sickle cell and other genetic disorders. Gift of Life is a leading national bone marrow and stem cell registry that serves patients all over the world seeking donors for transplants. It was founded during the grass roots efforts to save the life of New Jersey leukemia patient Jay Feinberg, and has grown to become a leading global registry. Gift of Life is accredited by the World Marrow Donor Association, and is an affiliate donor registry of the National Marrow Donor Program and participant in the international Bone Marrow Donors Worldwide registry. Gift of Life added an in-house apheresis center in 2019 and cellular therapy laboratory in 2020, ensuring its commitment to quality and consistency every step of the way.

Oss, The Netherlands

Glycostem Therapeutics is a Dutch biotech company established in 2007. Glycostem Therapeutics has developed the world's first GMP compliant NK cell platform that is ready for industrial scale-up.

Nantes, France

GOLIVER THERAPEUTICS is a spin-off from the INSERM and University of Nantes (CRTI UMR1064-ITUN-Nantes Hospital), focused on developing cell-based Advanced Therapy Medicinal Products (ATMP) to respond to an urgent unmet medical need in transplantation. GOLIVER THERAPEUTICS aims to become a Worldwide leader inregenerative medicine in providing the first cell-based therapy product for life-threatening liver failures.

Unit 518 of the 5th Floor of Building 11W, Phase Two, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, China

Great Bay Bio (GBB), based in Hong Kong, is an innovative biotech company with a vision of Disruptive Revolution of Biologics Development. Committed to utilizing AI and other cutting-edge technologies, GBB aims to address the challenges of long timelines, high costs, and low success rates in drug development, and in industries involving bioprocessing, e.g., synthetic biology, IVD and CGT. Led by a team of experienced professionals in biopharmaceuticals and AI, GBB's members boast over 20 successful IND filings approved by both China and the United States. GBB has launched multiple proprietary AI biotech platforms; AlfaCell, an AI-enabled site-specific integration cell line development platform that resolves multiple developmental bottlenecks, including unpredictable cell line stability and labor-intensive screening during CLD. Additionally, the AlfaMedX platform is an AI-enabled cell culture media development platform, responsible for creating over 50 unique cell culture media that outperform commercially available CHO cell culture media. GBB has secured 40+ patent applications, related to AI-enabled biological platform. Recognizing the potential of these platforms, GBB has formed partnerships with over 20 leading domestic and international companies.

Palo Alto, California, United States

Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, let's transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation

84 October Hill Rd, Holliston, MA 01746, US

HRGN is a clinical-stage biotechnology company that uses a patient’s own stem cells that are grown on a hollow tubular scaffold to regenerate organ tissue damaged from cancer, trauma, birth defects or other diseases.

Natick, Massachusetts, United States

HebeCell was founded in 2016 by a group of scientists who wanted to push research in regenerative medicine and immuno-oncology farther than ever before. Our team of researchers includes multiple world-leading experts in stem cell biology, as well as experienced entrepreneurs and business developers. We operate a fully-equipped, state-of-the-art laboratory in Natick, MA, one of the world’s largest biotech hubs. Since 2016, we have grown HebeCell into a leading innovator in our field. Most importantly, we have developed and patented a method of producing allogeneic natural killer (NK) cells indefinitely from induced pluripotent stem cells (iPS cells) by suspending them in a liquid solution within specially engineered bioreactors. No other company or lab has this technology or these capabilities.

New York, New York, United States

Helocyte, Inc. (“Helocyte”), a company founded by Fortress Biotech, Inc., is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease (in particular, cytomegalovirus or “CMV”)

5th Floor, Building 5, Zone B, Phase V, Biomedical Industrial Park, No. 21 Dongyanli Road, Suzhou Industrial Park, Jiangsu Province, China

Xueji Bio is a stem cell biopharmaceutical company founded by overseas returnees. It is committed to regenerating blood cells through stem cells for cell therapy of various diseases and related drug research and development. The company's founding members are from famous universities at home and abroad, such as Stanford University, Harvard University, and Peking University. Based on the world's leading stem cell directed differentiation system, Xueji Bio uses in vitro produced platelets as its lead product to address the urgent need for platelets in diseases such as cancer, liver disease, critical illness, and blood diseases, as well as develop innovative drugs for various platelet abnormality-related diseases.

Alberta, Canada

Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions that are not adequately addressed by current treatments.

St-Sulpice, Switzerland

HemostOD is a biotech company based at the EPFL Innovation Park in Lausanne, Switzerland. They are a preclinical stage company developing a therapeutic platform inspired by platelet biology.

Palo Alto, California, United States

Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.

Chatsworth, California, United States

HIBM (Hereditory Inclusion Body Myopathy) is a progressive and debilitating muscle wasting disorder caused by a gene defect. It touches those betwen the ages of 20 to 40 and, although progression is slow, it typically leads to total disability within 10-15 years. HIBM Research Group is laboratory funded byARM (the Advancement of Research for Myopathies,a leading supporter in research toward the cure).

Cambridge, Massachusetts, United States

HighPassBio, an ElevateBio portfolio company, is working to advance a novel approach to treating hematological malignancies by leveraging T cell receptor (TCR)-engineered T cells, known as TCR T cells. The company’s lead program is designed to treat or potentially prevent relapse of leukemia in patients who have undergone hematopoietic stem cell transplant (HSCT). The technology was born out of Fred Hutchinson Cancer Research Center by world renowned expert, Dr. Marie Bleakley.

SUZHOU, JIANGSU 215000, CN

Jiangsu Hillgene BioPharma is a leading CDMO platform for cell therapeutics. Our shareholders include China SME Development Fund, Guokejiahe Fund, Haier Capital, Huapont life science, China Capital Management, etc. The company is headquartered in Wuzhong District of Suzhou, the beautiful shore of Taihu Lake, with a registered capital of 100 million RMB. At present, a nationwide network of production bases has been formed initially, consisting of the headquarters in Suzhou (10000m2 GMP facility constructed) and the production base in Shenzhen (8000m2 GMP facility under construction). Meanwhile, the production base in North Carolina that is under construction contributes to the global layout     Hillgene focuses on cell therapeutics' and  particular plasmid production platforms, suspended and serum-free culture of viruses, and fully enclosed process development of cells, providing one-stop services from discovery to product delivery. We have helped several partners successfully develop drugs including CAR-T, TCR-T, and stem cells. And we are dedicated to pushing more projects to a new milestone quickly and bringing more cell therapy drugs into the market to let patients enjoy the products. Cell therapy innovation inspired.

Derio, Spain

Histocell is a clinical-stage biopharmaceutical company, specialized in developing cell therapy medicaments and novel medical devices for regenerative medicine, with a therapeutic approach focus on the control of oxidative stress. We work to improve people’s quality of life by creating new Cell Therapy medicaments. Our headquarters is located at the Bizkaia Science and Technology Park (Spain), with facilities comprising a 65 m2 GMP certified manufacturing room for cell therapy medicinal products, several laboratories for quality control and R&D activities and a 2000 m2 medical device manufacturing plant. Our team meets the maximum quality standards through GMP and ISO 9001/2000 certifications. Company's pipeline includes medical devices for promotion of Natural Wound Healing (Reoxcare® , Vexoderm®), Dermatologic Tissue Regeneration (Histoessence®, Wharton Gel Complex®, Neofibrin®) as well as Cell Therapy programs based on adipose derived mesenchymal stem cells (AMSC) for Bone regeneration and based on HC016 cellular product (proprietary technology) for Acute Spinal Cord Injury and Lung disease. Finally, Histocell, as an authorized ATMP manufacturing laboratory, offers Contract Manufacturing Services for both GMP and GMP-like manufacturing of cell therapy products.

Modena, Italy

Holostem Terapie Avanzate is the first biotechnological company entirely devoted to development, manufacture, registration and distribution of Advanced Therapies Medicinal Products (ATMPs) based on cultures of epithelial stem cells both for cell and gene therapy. The main aim of Holostem Terapie Avanzate is to promote epithelial stem cell-based Regenerative Medicine for patients with no alternative therapeutic solutions. Holostem Terapie Avanzate is located into the Centre for Regenerative Medicine "Stefano Ferrari"​ of the University of Modena and Reggio Emilia

Hangzhou, CN

Hopstem Bioengineering Co., Ltd. was founded on January 2017 in Hangzhou, by neuroscientists and stem cell biologists from Johns Hopkins University. Hopstem has established world-leading iPSCs platform of neural differentiation and cell engineering. Hopstem has developed several critical patented technologies，as well as CMC platform for iPSC-derived cell therapy products. Hopstem has iPSC reprogramming patent, GMP iPSC line with global licensing rights, iPSC-derived cell product manufacturing and quality system, and a variety of cell therapy products and pipelines, targeting CNS diseases, optical diseases and tumor. Hopstem’s first clinical product - neural progenitor cell hNPC01 targets neural injury diseases such as stroke and traumatic brain injury, has received China's IND approval and entered clinical trials. Hopstem is committed to translating the most cutting-edge technologies to provide global patients with safe, efficient and affordable cell therapy products.

Kyoto, Japan

iHeart Japan​ is an venture company developing regenerative medicine products.

California, United States

ImmuneAGE Bio is the first drug discovery platform company focused on immune system rejuvenation.

San Francisco, California, United States

ImmuneBridge is developing allogeneic immunotherapies for cancer. Our core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cellular source for immunotherapies. We are currently pursuing natural killer cell products for hematological malignancies. Next we will use the unique advantages of our cellular source to tackle solid tumors. Platform ImmuneBridge is creating a platform of scalable allogeneic immune cell therapies from cord blood. Our proprietary technology, including a novel small molecule, expands cord blood HSPCs over 100,000-fold while maintaining full immune multipotency, with the ability to differentiate into cell types including NK cells, T cells and macrophages. Pipeline In the near term, our goal is to validate the economic and clinical benefits of our expansion technology by taking an expanded-HSC-derived NK cell to clinical trials for hematological malignancies. In the long term, our unique access to the modified and unmodified immune tree allows us to tackle the challenge of solid tumors with combinations of modified cells. Agile Discovery This agile and flexible allogeneic platform reduces costs of discovery and manufacturing, expanding commercially viable indications for cellular immunotherapy. Starting from cord blood has speed and cost advantages over iPSCs, including the ability to quickly match HLA types to target populations or select beneficial genotypes without the need to edit those features into a clonal iPS line. This enables rapid iterations of abundant and consistent sources of therapeutic cells.

Irvine, California, United States

Immunis Inc. is a private biotechnology company focused on the development of treatments for age-related and disease-related immune deficits. Immunis has developed a novel method to grow human cells for clinical use, and direct them to become highly pure populations of defined cells that secrete factors which benefit immune system development, modulation, and health. With age, every person experiences a reduction of factors which benefit immune system development, modulation, and health; our technology allows replacement of those factors. Our investigational product is all natural, all human, and represents a perfectly balanced set of immune modulators in naturally occurring relevant physiological concentrations. Immunis' first clinical trial is a Phase 1/2a study of the effectiveness of STEM in treating muscle atrophy, which every person experiences with age.

St. Louis MO

Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.

Seattle, Washington, United States

Immusoft is a cell therapy company focused on developing novel therapies for rare diseases using sustained delivery of therapeutic proteins from a patient’s own cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs them to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients and provide therapeutic benefit for many years. The company is based in Seattle, WA.

New York, United States

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bio’s platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic. For more information about the Company and its programs, visit www.IN8bio.com.

San Antonio, Texas, United States

INCELL manufacturesand develops effective treatments for unmet medical needs.

Boston, Massachusetts, United States

InGel Therapeutics is Harvard-spinoff, regenerative medicine biotech leveraging novel neuroprotective mechanisms to stop retinal degeneration. Our beachhead indication is Retinitis Pigmentosa, with future expansion opportunities which include Dry-AMD and Glaucoma.

Innsbruck, Austria

Innovacell Biotechnologie AG is an innovative biotechnology company that develops personalized cell therapies for treatment of incontinence.

San Diego, California, United States

International Stem Cell Corporation (OTCBB:ISCO) develops a powerful new stem cell technology called “parthenogenesis” that promises to significantly advance the field of regenerative medicine by addressing the significant problem of immune-rejection. Parthenogenesis utilizes unfertilized human eggs to create “parthenogenetic” stem cells (hpSC) that can be “immune-matched” to millions of persons of differing sexes and racial backgrounds. A relatively small number of hpSC lines could provide sufficient immune-matched cells to cover large parts of the world’s population. ISCO plans to create a bank of these valuable hpSC lines (UniStemCell™) to serve all populations across the world. Human parthenogenetic stem cells have great therapeutic potential, yet do not require viable human embryos, thus avoiding ethical issues. ISCO’s scientists are focused on using hpSC to treat severe diseases of the eye, the nervous system and the liver where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells. ISCO advances and operates three businesses: Lifeline Cell Technology, Lifeline Skin Care and Universal Stem Cell Bank.

Daejeon, South Korea

IntoCell is a Korea-based biotechnology company dedicated to the development and commercialisation of novel antibody drug conjugate (ADC) platform technologies.

Alexandria, Australia

Inventia Life Science is making advanced cell models easy for high impact discovery. The company's strong foundation of fundamental research has led to the development of proprietary solutions to generate high-quality advanced cell models that are reproducible and highly consistent. Built by scientists for scientists, our intuitive solutions integrate seamlessly with existing workflows, whereas our wide range of biofunctional synthetic matrices and application-driven models make your desired assays possible.

Lake Forest, California, United States

Invitrx Therapeutics, Inc. is a biotechnology company specializing in the culture and engineering of adult stem cells by which we develop innovative products and therapies that are used in aesthetics, wound closure, and healing as well as plastic and reconstructive surgery. Invitrx was founded in July 2003 by Habib Torfi following many years of research and clinical trials involving adult stem cell technology. The research was originally developed to treat patients suffering from burns, diabetic ulcers, ocular surface disorders, and other ophthalmic conditions. Methods were developed to harvest and concentrate stem cells, providing the bases for Invitrx's cytokine and growth factor technology that demonstrated remarkable results in anti-aging by reducing the appearance of blemishes, fine lines, and wrinkles. Thus, using Invitrx stem cell core technologies, the ReLuma skin, hair, and lash therapy product line was created. ReLuma cosmetic products were designed utilizing adult stem cell technology to rejuvenate and reactivate dormant cells. The entire line of ReLuma products, including hair care, are formulated with human adult stem cell conditioned media containing cytokines and growth factors (along with interleukins and matrix proteins) to help reduce signs of aging and promote a youthful, even-toned glow.

Doylestown, Pennsylvania, United States

IO Biosciences develops allogeneic, gene modified cell therapies that treat cancers. Leveraging a proprietary lifesaving gene editing system and cell source, we create a unique opportunity to develop and manufacture of-the-shelf gene modified cell therapies. Taking vision from concept to reality - literally starting as a virtual, home-based biotech start-up last year, IO Biosciences has evolved to a team of 5 with office space and lab facility. Our state of the art CRISPOR gene editing methods create a new generation of universal “plug and play” cell sources for research and gene modified cell therapies treating cancers. This innovative system allows current personalized therapies to be transformed into manufactured off-the-shelf treatments and will greatly improve patient access at a competitive price point.

Houston, Texas, United States

IPS HEART is the first induced pluripotent stem cell company to launch in 2014 around heart disease. With over $20 million+ of funded research, we were the first to publish our moon-shot approach showing extensive heart regeneration after heart attack with over 50%+ EF improvement vs control and a 70% reduction in fibrosis. We have created extensive new functional human heart muscle in our published studies thus validating our patented IPS small molecule platform approach. With a completed FDA PRE-IND meeting and GMP manufacturing, we plan to file the first IPS IND to start clinically in the United States.

Paris, France

iPSirius SAS, [pronounced ip-Sirius], is a French headquartered immuno-oncology firm, seeking to obtain a clinical trial authorization from the U.K.’s Medicines and Healthcare Regulatory Products Agency, to enable it to move its novel therapeutic cancer vaccine into a first-in-human trial in patients with non-small-cell lung cancer.

Evry, France

Created in 2005 through a collaboration between Inserm – Institut National Health and Medical Research – and AFM-Telethon – French Association against Myopathies – I-Stem is the largest French laboratory research and development dedicated to human pluripotent stem cells, embryonic origin or obtained by reprogramming gene. I-Stem is part of the Biotherapy Institute for Rare Diseases, which includes so far the four centers of research and development funded directly by the AFM Telethon. The specific vocation of I-Stem is to explore all the therapeutic potential of human pluripotent stem cells for applications in patients affected by rare diseases of genetic origin. In this context, our teams are developing two major areas of research. The first one is cell therapy, which aims to replace lost or diseased cells to other cells with the same characteristics, produced in the laboratory from pluripotent stem cells. The second area is pharmacology based on automated screening of large libraries of compounds with therapeutic potential, following modeling of molecular mechanisms associated with diseases, as revealed by the study of pluripotent stem cells from affected donors. I-Stem teams are currently working on a dozen genetic diseases that affect different organs. The Institute also hosts every year many researchers interested in other diseases and provides training and technology support.

Miami, Florida, United States

iTolerance is a privately held regenerative medicine company enabling tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, iTOL-100, we are advancing a pipeline of programs using both allogenic pancreatic islets and stem-cells that have the potential to cure diseases. Our lead program, iTOL-101 is being developed for Type 1 Diabetes and in a preclinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our follow-on candidate, iTOL-102 is leveraging significant advancements in stem cells, which allows a potentially inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes. Additionally, the Company is developing iTOL-201 for liver failure and iTOL-301 as a potential regenerative protein and cell therapy that leverages stem cell sources to produce proteins or hormones in the body in conditions of high unmet need.

Fitchburg, Wisconsin, United States

JangoBio is developing regenerative therapies to reverse hormone imbalances associated with aging and thereby mitigate the risk of developing a wide range of age-related diseases. Pharmaceutical treatments, such as hormone supplementation, do not address the underlying loss of function, and can have significant side effects.

Jasper Therapeutics, 2600 Bridge Pkwy, Redwood City, CA 94065, United States

Jasper Therapeutics is a biotechnology company focused on targeting mast cells and stem cells to treat chronic diseases. Their mission is to make a significant difference in the lives of patients suffering from these conditions.

Utrecht, Netherlands

Jeta's mission is to improve outcomes for transplant patients by providing the highest quality medical devices available. These tests will provide best in class solutions for post-transplant surveillance of disease relapse, as well as organ and stem cell transplant rejection. Jeta's systems will enable new applications, lead to improved laboratory workflows, lower per test costs and will ideally translate into better patient care and survival rates

Suzhou, Jiangsu, China

North Barrington, Illinois, United States

Jointechlabs is a regenerative medicine company that offers point-of-care medical devices enabling safe and cost-effective non-surgical treatments.

Palo Alto, California, United States

Juvena Therapeutics is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions.

Nes Ziona, Israel

Kadimastem (TASE:KDST) A clinical stage biotech company introducing a cutting-edge TECHNOLOGY PLATFORM for the Development, Manufacturing, and Bio-Banking of functional human cells, providing OFF-THE-SHELF TREATMENT for multiple indications featuring ALS and Type 1 Diabetes as our top two leading projects.

2355 Westwood Blvd, 139, Los Angeles, California 90064, US

Kairos Pharma is focused on developing cutting-edge therapeutics for cancer patients that reverse the inhibitory effects of cancer on the immune system. By doing so, we seek to transform the way cancer is treated by positively impacting patient outcomes while maintaining quality of life.

Arlington, Massachusetts, United States

Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse, but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing our innovative spirit and deep commitment to advancing the treatment of eye diseases. KALA BIO is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye. KALA BIO’s biologics-based investigational therapies utilize KALA BIO’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA BIO’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA BIO is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA BIO, please visit www.kalarx.com.

San Diego, California, United States

Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders.

Orange, California, United States

Corneal Surgery Devices

California,USA

Khloris Biosciences is a private biotechnology company located in the San Francisco Bay Area. We are dedicated to revolutionizing medical treatment and prevention of cancer and other diseases by harnessing the unlimited immunotherapeutic potential of induced pluripotent stem cells (iPSCs) for drug discovery, vaccine and cell therapies.

Tokyo, Japan

Kidswell Bio Corporation (KWB), formerly known as Gene Techno Science, has been growing by leveraging our expertise in Biosimilar field in Japan. By 2024, four BS products were brought to market by our partner pharmaceutical companies as outcomes of co-developments between the companies and KWB. Besides, KWB has engaged in research and development for regenerative medicine with stem cells from human exfoliated deciduous teeth (SHED) since 2019, which targeted pediatric diseases, orphan disease and intractable disease with the aim of achieving comprehensive healthcare solutions for patients suffering from these diseases as well as for their families and caregivers. On the 1st of April 2024, the regenerative medicine business became independent as S-Quatre Corporation (SQ). KWB and SQ lead biosimilar business and regenerative medicine business　respectively, and grow together as two pillars of Kidswell Bio group. キッズウェル・バイオ株式会社(旧株式会社ジーンテクノサイエンス)はバイオシミラー医薬品事業により成長してきた。パートナー製薬企業との共同開発の結果、2024年までに4つのバイオシミラー製品を日本にて上市させている。一方で、2019年からは、乳歯由来歯髄幹細胞を用いた再生医療の研究開発に着手し、希少疾患、難病に加えて、小児疾患を重点的なターゲットと定め、患者様、及びそのご家族や介護者の方を含めた包括的なケアを目指した研究開発を行なってきた。KWBは2024年4月1日にこの再生医療事業を専門に行なう子会社である株式会社S-Quatreを設立し、現在はキッズウェル・バイオグループとしてバイオシミラーと再生医療の両事業を展開している。

4, Rue Thénard, Paris, Île-de-France 75005, FR

Kiji Therapeutic, Incorporated in France and Spain in 2023, develops transformative off-the-shelf engineered cell therapies for life-threatening diseases. Kiji-TX has a platform to gene engineer iPSC derived MSC cells for a targeted and optimized therapeutic benefit. The first asset is engineered with IL10/CXCR4 and targets several autoimmune diseases.

Miramar, Florida, United States

Since 2012, we are a biotechnology company developing MSC exosome products for research and therapeutic purposes. We have focused on regenerative medicine and aesthetic applications by producing quality assured, GMP grade, purified nanovesicles in a 27,000 sq ft facility in Miami, Florida.

Princeton, New Jersey, United States

Kyowa Kirin is a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines. We work on some of the hardest to treat diseases where need is high, and potential for life-changing impact is possible. The North America organization includes three offices in New Jersey and California that focus on drug discovery, product development, and commercialization. Together, we work as a collaborative team to understand clinical needs and advance innovations that have a profound impact on patient lives. Our growth in North America relies on entrepreneurial team players who are willing to share their expertise and ideas in an environment that prioritizes innovation, diversity, integrity and “wa.” Each person plays a significant role in shaping the work we do and the results we deliver.

Edinburgh, United Kingdom

Bonn, Germany

Your partner for nucleic acid extraction, biobanking, genotyping, epigenetics, transcriptomics, NGS, proteomics and bioinformatics.

Mountain View, California, US

Life-saving therapies. Critical diagnostics. Breakthrough clinical trials. Life Couriers places hope in the hands of patients everywhere by being the world's most trusted logistics partner for crucial pharmaceutical and medical products. We are the worldwide market leader for radiopharmaceutical and stem cell logistics. We have taken this experience with the most time-critical shipments in the world to expand our services to biopharmaceuticals, cell and gene therapies, lab specimens, clinical trials, organ transplant, medical devices, and more. We understand a fundamental reality - that missing a delivery can mean losing a life. That is why we have intentionally curated our culture to be solely focused on patient outcomes. Our people care more and they are deeply committed to enhancing, enriching, and saving lives through the power of logistics. We are Life Couriers. Logistics for Life.

London, England, United Kingdom

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfT’s Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds of times the cancer killing ability they naturally possess.

Switzerland

Limula offers a unique technology supporting routine manufacturing of highly-personalised cell therapies. They provide a modular solution for on-demand cell and gene therapy manufacturing, addressing one of the biggest challenges in the field of medicine.

661 University Avenue, Suite 1002, Toronto, Ontario M5G 1M1, CA

LineaBio's mission is to enable the cell and gene therapy industry by providing access to high-quality, off-the-shelf iPSC lines manufactured under GMP that streamline drug product manufacturing. By allowing therapeutic developers to cut costs and accelerate timelines for GMP reprogramming, LineaBio strives to achieve its vision of making cell therapy universally accessible and affordable. Founded in 2023 by parent companies CCRM and OmniaBio, LineaBio draws on a team of iPSC experts that have been developing an iPSC platform for more than a decade.

Carlsbad, California, United States

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com.

Basking Ridge, New Jersey, United States

(Formally Caladrius Biosciences; NASDAQ: CLBS) Lisata Inc., (LSTA) a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease.

Miami, Florida, United States

We are a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Our lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. We believe that by using the same cells that promote tissue repair, organ maintenance, and immune system function, we can develop safe and effective therapies for some of the most difficult diseases and conditions associated with aging. We are currently conducting Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS), which is the current exception to our focus on aging. Our mission is to advance Lomecel-B™ and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Our philosophy is that healthy aging can be improved through regenerative medicine approaches. Life expectancy has substantially increased over the past century as a result of medical and public health advancements. However, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging – a period known as healthspan. As we age, we experience a profound decline, in both number and function, in our own MSCs, a decrease in immune system function, decline in blood vessel functioning, chronic inflammation and other issues. Our clinical data suggest that Lomecel-B™ addresses these conditions through multiple mechanisms of action, or MOAs, that simultaneously target key aging-related processes.

Basel, CH

Lyon, France

MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.

Madison, Wisconsin, United States

Your Dreams START HERE! Explore more than 180+ hands-on career programs ranging from animation to welding. Start your degree here and consider our dozens of direct college transfer options. Or simply take a class for fun! Our campuses are located throughout Madison, Fort Atkinson, Portage, Reedsburg and Watertown. Many classes and some entire degrees can be completed online from anywhere! Find flexible, affordable education that fits your life and goals. Our 93% job placement rate is proof that employers hire our graduates! If you are a jobseeker, consider applying to join the team. Our culture, benefits and rewarding roles make Madison College one of the premier employers in the Madison area. Our online communities provide a convenient place where current and prospective students, alumni, jobseekers and the community can easily connect and discuss topics related to Madison College. We want you to participate and encourage lively discussion while following a few house rules: -Be respectful. -Be honest. -Respect copyright and fair use. -Derogatory comments, including racially or sexually motivated, and sexually explicit materials are not permitted. -Follow the social media platform’s Terms of Use Agreement. -We reserve the right to remove content. Rules of Engagement Madison College is committed to providing a safe space for every member of our community. To do this, we monitor our social media accounts and will remove comments that are blatantly harmful (i.e. racist, misogynist, homophobic, transphobic) to underrepresented communities. We do not condone censorship, but as a public institution we will always err on the side of protecting the physical and mental well-being of our community members.

Erlangen, Germany

Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss

Santa Monica, California, United States

MAX BioPharma is a California-based biotechnology firm developing novel small molecule lipids, referred to as oxysterols, as candidates for therapeutic drugs for debilitating and fatal human diseases. These oxysterol molecules belong to the family of sterols that have the ability to stimulate bone growth, block the growth of cancer cells, and inhibit their ability to metastasize. The company is a pioneer in this new field of Oxysterol Therapeutics® and focused on translating our key science into use for two large unmet medical needs: bone formation (in fracture repair, bone tissue engineering, and osteoporosis) and cancer.

Delft, Netherlands

Meatable makes 100% real, delicious, guilt-free meat. With one cell, we are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time we increase food security, without compromising the culinary experience of eating tasty, real meat.

Carlsbad, California, United States

MediCell Technologies (MCT) believes that stem cells can bring unique and exceptional value to health care.We forms Strategic Partnerships with industry and academia entities to facilitate and accelerate preclinical development of stem cell therapies. We are working to advance the field of stem cell applications. Progenitor Biologics®, LLC and AT Scientific, LLC are wholly owned subsidiaries of MediCell Technologies DefenAge® is a brand of Progenitor Biologics.

Seongnam-si, South Korea

MEDIPOST is founded in 2000, and today MEDIPOST is leading the global stem cell therapeutics field with the world’s first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell(hUCB-MSC) product named CARTISTEM® for patients with knee Osteoarthritis(OA), launched in Korean market in 2012. MEDIPOST operates the largest private cord blood bank “CELLTREE®” in Korea with over 255,000 units of private cord blood units under storage. Each year, over 20,000 private cord blood units are collected and stored at CELLTREE®. MEDIPOST’s research and development is focused on novel off-the-shelf, allogeneic cell therapeutics using human Umbilical Cord Blood-derived Mesenchymal Stromal Cells (hUCB-MSCs) with clinical-stage assets in the disease areas of osteoarthritis (OA), broncho-pulmonary dysplasia (BPD) and Alzheimer’s disease (AD). MEDIPOST’s flagship product, CARTISTEM® (allogeneic Umbilical Cord Blood-derived MSCs + hyaluronic acid hydrogel composite) for knee osteoarthritis was approved in 2012 by Korea’s regulatory agency Ministry of Food and Drug Safety (MFDS) with Biologics License Application (BLA) label “Treatment of knee articular cartilage defects in patients with osteoarthritis (ICRS grade IV) as a result of degenerative disease or repeated trauma (without age limit)” PNEUMOSTEM® (allogeneic Umbilical Cord Blood-derived MSCs) for the prevention of Bronchopulmonary Dysplasia (BPD) in premature infants, completed the first-in-human Phase I safety trial in Korea and the randomized, placebo-controlled Phase II clinical trial is ongoing in Korea. Phase I/II clinical trial in the U.S. has been completed confirming safety with positive efficacy signals. MEDIPOST’s 2nd generation human Umbilical Cord Blood-derived Mesenchymal Stromal Cell (hUCB-MSC) pipeline code named SMUP-IA-01 is an off-the-shelf intra-articular injectable cell product for the patients with early to mid-stage knee osteoarthritis (OA).

55 chapel street, newton, massachusetts, united states

MelliCell develops therapeutics for diabetes and obesity using proprietary technologies that model of weight gain in human fat cells in vitro. Our core technology enables discovery of therapeutic targets and leads, while reducing the time and money required for efficacy screening. It efficiently turns human stem cells into fat cells and accelerates their growth to sizes that are thousands of times larger than conventional limits and that match the sizes of mature fat cells in adults. Changes in fat cell size are how adults gain (or lose) weight, and increased fat cell size predicts diabetes better than obesity per se. The products we develop will treat obesity and diabetes by shrinking fat cell size and by preventing compromised metabolism in enlarged cells. We differentiate ourselves from existing therapies (e.g. GLP-1 analogs, SGLT2 inhibitors, anorexiants, intestinal lipase inhibitors, insulin secretagogues) by focusing on adipocyte-intrinsic mechanisms of action enabled by our core technology.

York, GB

Mesenbio is a preclinical biopharmaceutical business based at the University of York. Its Cell Line Extracellular Vesicle therapeutic is aimed at delivering next-generation medicine to patients.

Melbourne, Victoria, Australia

Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.

Kawasaki, Kanagawa, Japan

Revolutionizing the Way We Treat Heart Failure Heart failure kills more people globally than any other ailments, yet there is no ultimate treatment for the condition. Our goal is to develop and commercialize an effective and reasonably-priced therapy for heart failure using a specific fibroblast cells we call “VCF”, that we obtain from the patient’s own heart. Our approach to heart failure therapy is quite different from other technologies in a sense that we do not want to replace what is “broken”, but rather we want to repair the damage by enhancing the cells’ own ability to heal.

Cambridge, United Kingdom

Metrion Biosciences is a specialist preclinical drug discovery CRO - your trusted partner for ion channel screening, cardiac safety screening and neuroscience assays. We provide our customers with a range of in vitro screening services, including cardiac safety (GLP hERG, CiPA panel of human cardiac ion channels) and neurotoxicology testing and phenotypic assays on a fee-for-service or collaboration basis. We pride ourselves on being able to provide a flexible and cost effective service with an unparalleled level of expertise. Collectively, we have 250 years experience managing ion channel research programmes.

Worcester, Massachusetts, United States

Metro International Biotech, LLC is a privately-owned clinical-stage pharmaceutical company that has established the most comprehensive portfolio of proprietary drugs for the treatment of various diseases.

Providence, Rhode Island, United States

Microtissues® is a privately held company advancing technologies and applications of 3D cell culture. The company's products stand above the rest because they are designed to create more natural and more reliable 3D cell culture environments based on cell-to-cell interactions in convenient and consistent formats that generate high content information. The company's lead line of products, the 3D Petri Dish®, is serving the needs of researchers in a wide range of areas including cancer research, stem cell biology, toxicity testing, developmental biology, drug discovery, regenerative medicine and tissue engineering. In addition to products for basic research, Microtissues® is using its platform technology to pursue applications in drug discovery and cell therapy. Need more information or for a sample please email us at info@microtissues.com...

Waltham, Massachusetts, United States

Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. NCT04020575 is Minerva’s first-in-human trial of huMNC2-CAR44, a CAR T that targets the MUC1* growth factor receptor, for the treatment of metastatic breast cancers, 95% of which express a MUC1*. We are now expanding the current clinical trial to include our second CAR-T product that greatly increases persistence. The Company is rapidly accelerating its pipeline that includes next-gen CAR-T products, a straight antibody therapeutic and a small molecule therapeutic which are both for the treatment of cancer metastasis. Our track record of scientific breakthroughs is a testament to our visionary team and our collaborative culture. Join us in changing the world.

760 Parkside Ave, Brooklyn, New York 11226, US

Diagnostics We build innovative diagnostic and monitoring tools that empower people to make better decisions about their health. Drug Discovery We translate early-stage research into customized RNAi and CRISPR Cas9 animal and cell models to accelerate drug development. Therapeutics We identify and validate new drug targets, unleashing the commercial potential of RNAi to benefit people on a global scale. Established in 2010 to harness the power of RNAi and genetic engineering technologies developed by our founders in the labs of the world's leading experts at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, and Harvard Medical School, Mirimus creates innovative research and clinical technologies to address health issues on a global scale. Today, Mirimus markets multiple unique and high-value drug discovery and diagnostic products and services, and is advancing a pipeline of therapeutic candidates in partnership with leading biopharma companies to create novel high-impact health care solutions that benefits society on a global scale. Mirimus' ability to leverage its cutting-edge science and proprietary technology platforms to rapidly create new, affordable technology and products at scale is core to the way we work. We embrace diversity and creativity and have a proven track record of innovative problem solving—which led to our recognition as a $1M grand prize winner of the XPRIZE competition by developing a radically affordable, rapid, non-invasive methodology for mass COVID-19 testing—driving us to make better drugs and detect disease earlier. At Mirimus, our ingenuity, respect for our colleagues' ideas and creativity, executional agility, and a commitment to global health equity combine to create a unique culture of innovation that delivers measurable progress.

Montreal, Quebec, Canada

Cell and gene therapy promises to one day cure any pathology; Modulari-T’s MARC Platform produces the tools to fulfill that promise.

San Diego, California, United States

Modulo Bio simulates the neuroimmune system to find medication candidates that target microglia cells. The organization's proprietary neuroimmune system mapping platform is designed to identify potential treatments for neurodegenerative diseases such as ALS and FTD.

51 Outlook Circle, Pacifica, CA 94044, United States

Founded in 2021 and based in San Francisco, Monomer Bio specializes in wet-lab productivity and automation software built for cell biology workflows. We aim to transform the landscape of scientific research by automating laboratory processes while capturing clean, well-structured data. We have delivered a number of automated cell culture solutions to customers working in the fields of drug discovery and cell and gene therapy. We also consult: whether you need help deciding what instruments to buy, need help getting your instruments and software to talk to each other, or need something custom-built (software or hardware), drop us a note at hello@monomerbio.com. We love deep dives with your biologists, engineers, technicians, or executive team.

Missoula, Montana, United States

Montana Medical Researchis a dedicated independent research center that specializes in the management and coordination of phase II-IV clinical research trials.

Montreal, Quebec, Canada

Morphocell Technologies Inc. is a regenerative medicine company focused on the development and commercialization of stem cell therapies and engineered tissues targeting liver failure. The Company is a spin-off of the Hepatology and Cell Therapy lab of Sainte-Justine University Hospital Center, in Montreal. Founded in April 2018 on the technology developed by Dr.Paganelli, a pediatric transplant hepatologist and stem cell scientist, Morphocell Technologies aims at bringing to market the first effective treatment for acute, chronic and acute-on-chronic liver failure.

MPC Therapeutics, Plan-les-ouates, Geneva, Switzerland

MPC Therapeutics is a biotechnology company focused on cellular rejuvenation to fight cancer & degenerative pathologies. They develop a class of compounds with applications in immunotherapy and metabolic diseases. The company is founded on the belief that they can manipulate cell behavior to fight cancer and degenerative diseases.

Berlin, Germany

MyoPax uses its proprietary muscle stem cell technology to develop advanced regenerative therapies and fight the devastating consequences of muscle diseases. MyoPax is a spin-off from Charité Universitätsmedizin and Max-Delbrueck-Center for Molecular Medicine in the Helmholtz Association.

San Diego, California, United States

NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, by ensuring high cell viability required to advance cell-based research. We develop and deliver microfluidic based solutions that are affordable, compact, and easy-to-use. Our expanding portfolio of instruments and consumables enable biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.

Gosselies, Belgium

Ncardia's hiPSC products portfolio encompasses a broad panel of cardiovascular and neural cells. In addition, the company delivers the Cardioplate™ product line of quality-controlled ready-to-use assay plates.

Knoxville, TN, USA

NellOne Therapeutics is passionate about its work to pioneer advances in the field of tissue regeneration, developed over the course of many years of scientific research and exploration. Our highly experienced team is committed to improving outcomes for millions of patients across the world, and creating a successful business that truly makes a difference.

Rapperswil-Jona, Switzerland

Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology. Our lead product, Grafalon®, has been used for over 30 years to treat patients and is available in more than 40 countries world wide. It has approval for use in immunosuppressive therapies for prevention of graft- versus- host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation and in treatment of aplastic anemia.

Mountain View, California, United States

NeuCyte is a biotech company focused on CNS drug discovery. Its SynFire® technology uses human iPSC-derived neurons to identify drug targets, test efficacy, and safety of novel compounds for neurological disorders.

Shanghai, China

Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis, through internal discovery and external collaboration, with emphasis on innovative immuno-oncology products.

Rensselaer, New York, United States

Rensselaer, New York, US

Neural Stem Cell Institute is a regenerative medicine company that focuses on developing stem cell therapies for diseases of the nervous system.

Geneva, Switzerland

To help get better and safer medicines to patients faster. We developed a robust technology and translated it into a unique product which today serves as the gold standard for in vitro testing of products and pharmaceuticals.

Tel Aviv, Israel

NeuroKaire is a precision psychiatry and neurology company using a cutting-edge combination of stem-cell technology, genomics, and AI for treatment optimization and effective drug development. NeuroKaire uses this innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Clarksville, Maryland, United States

Neuronascent (NNI) is a small corporation, that we believe has an over-sized opportunity to improve the well-being of millions of patients suffering from chronic neurodegenerative disorders that lack any disease-modifying therapeutic options. As we move toward this goal, we have built a strong track record of meeting critical drug-development milestones, which is of importance to investors and future pharmaceutical partners. Using a novel screening process developed by Neuronascent, the Company was able to identify small molecule therapeutics that generated new neurons in the brain and ensured that these new neurons survived to functionality under neurodegenerative conditions. These small molecule candidates proved successful not only on human neuronal progenitors in a lab dish, but showed the same capacity in animal models of chronic neurological diseases. NNI's synthetic therapeutic candidates are optimized and patented. These orally available candidates have been found to be safe in all testing to date. Our lead candidate for Alzheimer’s and potentially for Parkinson’s disease, has completed in first-in-human testing (Phase 1a), with no significate safety concerns for this therapeutic in healthy aged subjects. The Company is based in Clarksville, Maryland, United States.

South San Francisco, California, United States

Neurona is a biotherapeutics company developing neural cell therapies with single-dose curative potential for the treatment of chronic neurological disorders. Based on a novel neural cell lineage pioneered by the company’s scientific founders, Neurona has built a robust regenerative platform and is developing neuronal, glial, and gene-edited cell therapy candidates that provide long-term repair of dysfunctional neural networks for multiple neurological disorders.

The Biosphere, Drayman's Way, Newcastle Helix, Newcastle upon Tyne NE4 5BX

We’re here to accelerate your therapy’s journey through the complexities of drug discovery and development. Putting innovation at the forefront of our capabilities, industry-leading experts help you confidently and proactively answer critical questions around the safety and efficacy of your product with our gold-standard in vitro models. By harnessing the power of predictive data, we navigate this crucial step efficiently and cost-effectively to maximise the potential of your therapy achieving clinical and market success. By combining our unique expertise with cutting-edge technologies, we’ve created predictive in vitro models that offer targeted solutions to your complex problems. Our tissue model platforms, including retina, kidney and lung, reliably and accurately mimic in vivo physiology to take the guesswork out of drug development – providing answers to your questions and a window into the future of your therapy. Our intelligent preclinical models provide the reliable data you need to identify, avoid and mitigate risks and failures. By better understanding how your therapy will interact in vivo, you can make assured decisions to reduce drug attrition and give your safe and efficacious asset the best chance of reaching patients. In a nutshell, we help you save money, save time and save lives by getting ahead of the game.

Jerusalem, Israel

NewStem is a biopharmaceutical company focused on Human Pluripotent Stem Cells (HPSCs) in general and Human Haploid Pluripotent Stem Cells (HHPSCs) in particular. These cells have the potential to change the face of medical research as they hold a pivotal role in regenerative medicine, disease therapy and cancer research. NewStem possesses pioneering intellectual property, reagents and experience related to the isolation and differentiation of HPSCs, their genetic manipulation, immunogenicity, tumorigenicity and their unique capacity in disease modeling. With this innovative research, and specialized drug and gene screening capabilities. NewStem is currently the only company worldwide to develop products based on this paradigm changing proprietary tech-nology, licensed from Yissum, Hebrew University’s technology transfer company, based on the findings and in-ventions of Prof. Nissim Benvenisty, of the Azrieli Center for Stem Cells and Genetic Research, The Hebrew University of Jerusalem.

Hälsovägen 7, Karolinska Institutet Science Park, Novum 8D, Huddinge, 14157, SE

NextCell Pharma is an innovative Biotech growing out of the need for Advanced Therapy Medicinal Products for Autoimmune Disease and Transplantation. Cellaviva, the first Swedish family saving stem cell bank, with its expertise in umbilical cord stem cells and Diamyd Medical with its interests and investments within autoimmune diseases made a natural partnership for creating NextCell Pharma. Clinical trials testing NextCell Pharma's first product, ProTrans,has started in Novermber 2018. #nextcellpharma #cellaviva

Watertown, Massachusetts, United States

Nido Bio is translating today’s neuroscience breakthroughs into tomorrow’s treatments for severe neurological diseases. Leveraging human genetics, we develop precision medicines that address the fundamental biology of disease and restore healthy cell function. NIDO-361, our clinical-stage candidate, is a treatment for Spinal and Bulbar Muscular Atrophy which is a rare and debilitating neuromuscular disease. Additional pipeline programs center around a novel target with the potential to address multiple disease mechanisms and that has broad clinical application across neurodegenerative and peripheral inflammatory diseases. We are creating a sustainable pipeline for the company by utilizing a functional genomics discovery platform based on human cell lines to identify novel targets. Through our approach we seek to transform patient lives in meaningful ways.

Dueren, Germany

Innovation for you! With two decades of experience, NIPPON Genetics EUROPE stands at the forefront of life science and biotechnology innovation. Based in the heart of Europe, we're your global partner in delivering cutting-edge, high-quality products designed to meet the unique needs of the life science sector. Our extensive product lineup is at the cutting edge of technology, featuring instruments such as Real-Time PCR systems, Gel Documentation systems, and spectrophotometers. We're particularly proud of our newest breakthrough: the FastGene® FAS-X Gel Documentation System. Built with our Blue/Green LED technology, it has been honored with the German Innovation Award 2024! But that's not all—we also offer a comprehensive range of reagents for DNA and protein electrophoresis, PCR, cell biology, and more. Our best-selling Bambanker™, a serum-free cell cryopreservation medium, is trusted by researchers worldwide. At NIPPON Genetics EUROPE, we pride ourselves on our exceptional quality standards, customer benefits, and reliability. With a distribution network in over 70 countries, we're dedicated to helping you achieve your scientific goals. Interested in our products or exploring collaboration opportunities? Have a look at our website: https://www.nippongenetics.eu/ or reach out to us at info@nippongenetics.de.

London, United Kingdom

NK:IO reimagines cancer treatment. By harnessing the potential of the innate immune system, we are developing ground breaking NK cell and small molecule therapies targeting both haematological and solid tumours. Our technologies are built on pioneering research carried out by Hugh Brady and Matthew Fuchter at Imperial College, London. Based on their discoveries we have developed three interrelated, proprietary technology platforms.

Reutlingen, Germany

NMI TT Pharmaservices is a Contract Research Organization dedicated to provide experts services to customers in Pharma, Biotech and Academia. Our business is focused on high-quality services and R&D support, for preclinical drug discovery & development, drug mode of action studies, predictive toxicology, safety pharmacology, and biomarker screening. Our main competences are - Protein Profiling Services - Custom Cell Services - Electrophysiology Services NMI TT GmbH, a privately-held company founded in 2002, is a subsidiary of the NMI Natural and Medical Sciences Institute at the University of Tübingen, a private research foundation, with operations in Reutlingen and Berlin, Germany.

Vancouver, British Columbia, Canada

Notch is an early-stage biotech company, working to maximize the benefit of cell therapies through a proprietary T cell-production platform which combines sophisticated product design with commercial-compatible processes to enhance patient outcomes. Notch’s iPSC-based technology platform allows for precision control of notch signaling, which removes several critical limiting factors in the development of cell therapies, delivering the ability to design and manufacture a uniform and unlimited supply of therapeutic T cells.

Mont-Saint-Guibert, Belgium

Novadip Biosciences is a clinical-stage biopharmaceutical company founded to design, develop, and bring to the market a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment. Novadip’s lead allogeneic product, NVD-X3, employs a matrix containing multiple bioactive factors that induce accelerated tissue healing. Designed as an “off-the-shelf” product, NVD-X3 can be shipped and stored at room temperature and offers superior intraoperative handling characteristics. Novadip is also developing NVD-003, an autologous therapy derived from ASCs as a potential single treatment to save limbs and restore mobility in patients with congenital pseudarthrosis of the tibia (CPT). CPT is a rare pediatric bone condition.

Gaithersburg, Maryland, United States

Nuo Therapeutics, Inc. is a biomedical company that develops and commercializes individualized wound care therapies that harness a patient’s innate regenerative ability to stimulate wound healing. The Company’s flagship product, Aurix is a biodynamic hematogel derived from the patient’s own platelets and plasma, which is used at the point-of-care to jumpstart the natural healing process in a broad range of chronic wounds, including diabetic foot ulcers, venous leg ulcers and pressure injuries.

New Orleans, Louisiana, United States

Obatala Sciences offers contract research services and research products to laboratories in industry and in academia. Our clients include major pharmaceutical companies, US government entities, contract research organizations, non-profit organizations, and academic research laboratories. Our areas of expertise include obesity, diabetes, energy metabolism, musculoskeletal system biology, and wound healing. ObaCell™, a unique fat tissue model, is a great tool for disease modeling and drug screening. Obatala Sciences can provide data in various areas depending on your interest including proteomics, genomics, functionality, and adipokine secretion. We also have the capability of forming white or brown fat tissue upon request.

La Habra, California, United States

Oculogenex is a biopharmaceutical company founded and directed by an ophthalmologist retinal surgeon with patients in mind. It was founded out of passion and frustration shared with patients losing vision due to lack of therapeutic options. We have professional and scientific experience with retinal diseases, genetic variations in retinal and optic nerve diseases. We have built a team of experts in animal models of macular degeneration, antioxidant therapies for macular degeneration, medical and surgical treatments of retinal diseases and drug delivery methods. This specialized team has been built to utilize genetic engineering technology to improve vision for patients with degenerative eye diseases.

Galway, Ireland

Omnispirant is a biotechnology company that develops a novel platform technology using inhaled stem cell exosomes for treating respiratory diseases.

New York, New York, United States

Oncolyze is developing therapeutics that exploit a novel mechanism of action for the targeted and selective lysis of cancer cells and cancer stem cells.

Kawasaki, Japan

OncoTherapy Science, Inc. provides pharmaceutical companies with yielded drug candidates by using outcomes obtained from joint research with universities and companies. These outcomes include oncogene information isolated by comprehensive analysis of genes specifically expressed in cancer cells and functional analysis information of proteins produced by oncogenes and other gene products. We have also been performing research and development business regarding medications.

Kraków, Poland

Polish medtech startup ONGENO has a therapy developed by Dr. Wojciech Orlowski, M.D., which has been proven in the first phase of the experiment to lead to improved sclerosis patient health, reduced disability, and lack of disease progression in the long term.

4340 Duncan Ave., St Louis, Missouri 63110, US

OpenCell Technologies™ is a leading innovative company developing a cutting-edge, continuous, scalable, non-viral, cell agnostic soft-poration transfection technology. Our breakthrough platform enables efficient continuous delivery of large cargos into challenging cell types, expanding the frontiers of cell engineering in Biopharma and Cell & Gene Therapy. With precise control at the single-cell level and high throughput, our OpenCell™ technology drives scientific discovery and enhances the effectiveness, affordability, and scalability of current cellular therapies. We empower researchers and clinicians to achieve remarkable advancements in biomedical science and clinical practice.

Madison, Wisconsin, United States

Opsis Therapeutics is a company focused on advancing the pipeline of cell replacement therapies targeting ocular diseases. Leveraging innovations in induced pluripotent cell (iPSC) generation, retinal cell differentiation, and functional biomaterials, Opsis Therapeutics is developing cell therapies for patients with dry age-related macular degeneration (AMD), inherited macular degenerations (IMDs) and inherited retinal diseases (IRDs). Founded in 2016, Opsis Therapeutics is a joint venture of FUJIFILM Cellular Dynamics and David Gamm, M.D., Ph.D., and is headquartered in Madison, Wisconsin.

Galway, Ireland

Orbsen Therapeutics Limited aims to become a leading company in the development of regenerative medicine therapies across a range of diseases and medical conditions. We are developing a novel proprietary technology that permits the isolation of pure and defined stomal cells from human tissue and a range of other species. The multi-species elements allow our technology to move seamlessly from the research laboratories to the clinic. The technology is designed to ensure that resulting therapies comply with the forthcoming stringent EMA and UK BSI guidelines regarding the purity and definition of cellular therapies. We believe that our technology will set the standard for regenerative medicine into the future. Orbsen Therapeutics was originally formed in 2006 as a spin out company from REMEDI, Ireland's Regenerative Medicine Institute in NUI Galway. Founded and led by some of the leading scientists in the field of regenerative medicine we operate from within the Orbsen Building, on campus at NUI Galway, which houses REMEDI's state of the art research facilities. The company has already participated in EU FP7 funded research progammes and has a significant research pipeline coming to fruition over the coming years.

Menlo Park, California, United States

Orca Bio is a clinical-stage biotechnology company developing a pipeline of high precision allogeneic cell therapy products that are designed to safely replace patients’ diseased blood and immune system with a healthy one. Our manufacturing platform sorts donor blood with single-cell precision and a high level of purity and speed, enabling us to create proprietary, optimal therapeutic mixtures of immune and stem cells that have the potential to transform allogeneic cell therapy. Our talented team is driven by a passion for science and compassion for patients.

London, England, United Kingdom

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist. For more information, please visit www.orchard-tx.com.

Miami, Florida, United States

OrganaBio was founded in 2018 with the mission to become the hub for tissue sourcing, clinical sample processing and contract manufacturing services to support cell and gene therapy developers around the globe. At our core, we continually apply a data-driven approach with meaningful insights across our strategically located facilities to provide solutions to our clients where they need it most. Headquartered in Miami, Florida, OrganaBio delivers products and services that span the full development lifecycle – from proprietary tissue supply chains and cellular starting materials to expert development, testing, and other support services that expedite the path to clinical translation.

Pittsburgh, Pennsylvania, United States

Organoid Therapeutics is developing organoid-based technologies to correct hormone deficiencies in patients and streamline drug discovery and toxicology testing in the lab.

Seattle, WA 98208, US

The future of preclinical drug discovery is engineered tissue. The founders of OrganOmics have developed cutting-edge, live human brain tissue models derived from stem cells. They have partnered with the neurosurgeons to source patient-derived cancer tissue to induce a realistic cancer pathology. Their patented microfluidic platform automates the assay, detailing drug responses of thousands of tissues generating high-content data. This vast, cellular response data is processed through artificial intelligence to predict the clinical outcomes of each candidate drug.

Germantown, Maryland, United States

Orgenesis is a global biotech company that has been committed to unlocking the potential of decentralized cell and gene therapies (CGTs) since 2012. Orgenesis established the POCare Network in 2020 to bring academia, hospitals, and Industry together to make these innovations more affordable and accessible to patients. In 2022, the POCare Services business unit responsible for developing and managing the decentralized POCare Centers and proprietary OMPULs was formed. Orgenesis will continue to focus on advancing to market through various partnerships its CGTs to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production.

Austin, Texas, US

OriGen Biomedical is a leading producer of cryopreservation and cell culture products. OriGen’s focus is to produce a range of products to support the treatment of cancer, genetic conditions, and other life-threatening diseases. OriGen Biomedical® products are designed with the patient and user in mind and we strive to maintain excellent customer service to ensure that patient care is the priority. OriGen is a growing, privately-held medical device manufacturer founded in 1997 and headquartered in Austin, Texas. Quality is the foundation of all product designs at OriGen, and each product is produced with the intention of improving patient health. OriGen is certified annually to ISO 13485 standards and regularly inspected by the FDA, MDSAP, ISO certification organizations, and our customers. Our European distribution center serves to reduce the time to patients by providing stock products for quicker turnaround times out of the Netherlands.

Fujisawa, Kanagawa, Japan

This company is a spinout from Takeda Pharmaceuticals and Kyoto University, focusing on the development of induced pluripotent stem cell (iPSC) technology-based regenerative medicine.

San Francisco, California, United States

Building a Healthier Future Our mission is to improve the health, vitality, and longevity of human beings through bioengineering. Who We Are At Ossium, we believe that science is humanity’s best weapon in the fight against disease, and we embrace the challenge of mobilizing the world’s healthcare ecosystem to win that fight. In pursuit of this goal, we empower our employees, maintain the highest standards of excellence, and are a force for good. PRINCIPLES The values we live by Impact We are mission-driven and results-oriented. We believe that a healthier world is a better one and that our work should drive positive change. Truth Embracing the truth empowers us to learn from both our successes and our mistakes. We follow the data wherever it leads. Ownership We hold ourselves and each other to the highest bar. We care deeply about the work we do and know that even the smallest details can make a difference.

Bentley, Australia

Ozgene offers the full spectrum of capabilities to design, generate, breed & phenotype your mouse models. It was not that long ago that a mouse was just a mouse but, for the team at Ozgene, a mouse represents a way to advance humanity. Started 15 years ago, today, Ozgene is one of the leading companies providing genetically customised mice for researchers around the world. With best in industry timelines using their goGermline embryos other services include knock-in, knockout, humanized and transgenic mouse models, breeding and husbandry, validation and phenotyping and Geneoz VMS. Ozgene has developed a new goGermline approach, which is a revolutionary new technology to generate knockout and knock-in mice fast and efficiently, while improving animal welfare. Ozgene is now able to complete projects in less than 6 months. Whilst, Ozgene is an Australian company, 80% of their clients are located overseas and shipments leave the Ozgene facility almost daily for laboratories, small academic institutions, research institutes, biotechnology companies and multinational pharmaceutical companies in the US, Europe, Asia, South America and New Zealand. CEO and Co-founder, Dr Frank Koentgen, and the Ozgene team have over 20 years of experience in the generation of genetically modified mice. It begins even before Ozgene was born, when Dr Koentgen generated the first knockout mouse from the C57BL/6 mouse strain in 1993. Work has been published in scientific journals such as Cell, Nature, Science, Immunity, PNAS and Nature Medicine.

EGF-5, Bangalore Bioinnovation Centre, Bangalore Helix Biotech Park

Pandorum is a biotechnology company based out of the US and India, working in the field of Tissue Engineering and Regenerative Medicine. With its distinct synergy of life science, engineering and clinical competences, at Pandorum, we have developed a proprietary technology platform which combines therapeutic exosomes with anti-inflammatory, anti-fibrotic properties derived from clinical grade human stem cells and biomaterials with tissue-mimetic properties – to promote efficient regeneration of human tissues, such as cornea, liver and lung. Pandorum has been supported by a number of Govt. grants (BIG, SBIRI) and awards, and have raised funding from marquee investors and VCs. We are proud to have a world-class team of scientists, engineers, clinicians, and key opinion leaders deeply engaged in the product development and clinical translation. Pandorum's efforts towards clinical translation of its products have been supported by renowned medical Institutions such as, are Northwestern Medicine (Chicago, US), Medical University of South Carolina (Charleston, US) and Dr. Shroff’s Charity Eye Hospital (New Delhi, India). Pandorum is also proud to be an Endless Frontier Labs (EFL) start-up, NYU Stern School of Business, Life Sciences Cohort -2023. At Pandorum our efforts are dedicated to make Regenerative Medicine an efficacious and scalable mainstream reality, to be able to address the sufferings of millions across the globe affected by various diseases of unmet clinical needs

3210 Merryfield Row, JLABS, Papillon Therapeutics, San Diego, California 92121, US

Papillon Therapeutics is a clinical stage biotechnology company advancing multi-systemic genetic medicines for diseases with neurologic, cardiac, and other tissue pathologies, including Friedreich's ataxia, Danon disease, and Alzheimer's disease. Inherited conditions often cause degeneration of multiple tissues throughout the body, inspring our approach to develop therapies that offer patients lifelong multi-systemic therapeutic benefit from a single treatment. Our clinical stage program, a gene modified hematopoietic stem and progenitor cell (HSPC) therapy for treatment of Cystinosis, reported positive data in a Phase 1/2 clinical trial and is being advanced by Novartis. Building on this success, we are advancing gene modified HSPC treatments for life threatening conditions with neurologic disease, including Friedreich's ataxia, Danon disease, and Alzheimer's disease. Funding awarded by the California Institute of Regenerative Medicine (CIRM) and NIH to our scientific founders totals over $30 million towards the Cystinosis, Friedreich's ataxia, and Danon disease programs.

2749 East Parleys Way, Suite 100, Salt Lake City, UT 84109, US

Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant challenges of male infertility. We recognize the critical gap in male fertility treatment and are committed to helping people on their path to parenthood. Our innovative in-vitro spermatogenesis (IVS) technology is poised to transform the fertility landscape, offering new hope and innovative solutions to those struggling to conceive. Led by a team of world-renowned scientists and physicians, we are advancing research into clinical applications. Our mission is to make parenthood a reality for more families through ethical, scientifically advanced fertility solutions. Did you know? *1 in 8 couples struggle with infertility. *50% of in vitro fertilization (IVF) procedures fail. *50% of infertility is linked to men. *Male infertility treatment has been stagnant since 1992. Paterna is the first to develop a truly new treatment for male infertility since then. With a strong foundation in science and a commitment to innovation, Paterna BioSciences is uniquely positioned to lead the next generation of male fertility treatments. We are actively seeking funding to accelerate our clinical development and commercialization efforts, bringing our life-changing technology to families worldwide. We help make parenthood possible. Learn more at www.PaternaBio.com Contact us: info@paternabio.com A New Paradigm in Human Reproduction.

Monrovia, California, United States

Pathways to Stem Cell Science promotes the advancement of stem cell science and regenerative medicine through the combined provision of contract research services and educational programs. The organization seeks to lower the barrier to working with stem cells by providing cost-effective support for customized scientific projects. Their education programs enable students of all ages, Pre-K to 12 and college to do hands-on work with stem cells, and provides them with the skills, inspiration, career education and professional experiences needed to forge successful bioscience careers. They also support public outreach and provide specialized industry training to professional scientists.

4721 Calle Carga, Camarillo, California 93012, US

PBS Biotech aims to be the leading provider of innovative, single-use bioreactor systems specifically designed to address the unique challenges of cultivating shear sensitive cell types for cell therapy development. Our offering includes scalable, cost-effective disposable solutions designed to take you from benchtop R&D to large-scale cGMP manufacturing, and expert process development services to help solve cell culture challenges and accelerate your path to commercialization. To learn more, contact our sales team at sales@pbsbiotech.com or visit our website at www.pbsbiotech.com

907 Westwood Boulevard, Suite 384, Los Angeles, CA 90024

Pelage is a clinical-stage regenerative medicine company developing novel treatments for hair loss, including androgenetic alopecia. Based on discoveries in stem cell biology made by Pelage's scientific co-founders, the company's novel approach is designed to reactivate dormant hair follicle stem cells and restore the body's ability to grow hair naturally.

Eatontown, New Jersey, United States

Personal Cell Sciences is a Life Sciences company that specializes in developing and distributing personalized Adipose Derived Stem Cell based anti-aging, topical skin care products using individual's own stem cells.

Poway, California, United States

Personalized Stem Cells, Inc. (PSC) is raising the standard of Stem Cell therapy. We are committed to providing high-quality stem cell processing services, as well as excellent technical, clinical, and regulatory support to physicians, clinical investigators, and patients.

Skiffervägen 48, 224 78 Lund

Phase Holographic Imaging is a company that specializes in live cell imaging and analysis systems, enabling label-free kinetic live cell studies during physiologically optimal conditions. They also provide time-lapse cytometers for long-term imaging and analysis of cell cultures using a patented method that allows living cells to be studied without the use of labels or dyes.

550 C Street West, Joint Base San Antonio-Randolph, Texas 78150-4727

Discover Phycin's pioneering solution for ocular injuries – a groundbreaking therapy derived from the miraculous world of algae! As a leading innovator in growth factor technology, we present an unparalleled approach to transform the treatment of corneal damage for both military personnel and the general public.

14, Rue Jean-Antoine de Baïf, Paris, Île-de-France 75013, FR

PK MED is a French innovative biotech company, privately owned and established in 2019 with the support of Truffle Capital, a prominent European Venture Capital firm specializing in Life sciences. PK MED was created around a small team of passionate and experienced experts in pharmaceutical and medical sciences, drug delivery and biomaterials design. PK MED specializes in the innovative development of custom-designed, injectable, and biodegradable micro-implants. Our expertise spans across critical healthcare domains, focusing on drug delivery systems for rheumatology and enhancing cell-homing techniques to improve bone marrow transplantation outcomes. The company has developed a portfolio of early projects in indications with high unmet medical needs, starting with Gout flare, Osteoarthritis and Hemoglobinopathies.

Stevenage, England, United Kingdom

Plasticell is a biotechnology company that develops novel therapies through precise manipulation of stem cells and more differentiated cell types using award-winning combinatorial screening technology. Technolgy Innovate cell-based combinatorial screening technology allows us to develop optimised protocols for cell expansion, cell differentiation, gene transduction, biomolecule production as well as the provision of human cells for use in drug discovery. Pipeline Out therapeutic projects include advanced cell and gene therapies as well as drugs discovered by screening rare human cell types derived from stem cells Visit our website www.plasticell.co.uk for more details.

Aachen, Germany

We at PL BioScience are experts in cell culture supplements derived from human Platelets. Our mission is to enhance the advances in cellular research and therapy with one forward-looking Technology: ELAREM™. The ELAREM™ Platform unites tailored cell culture supplements based on Human Platelet Lysate. The human origin combined with a rich growth factor content not only supports cell growth, but also enables various applications: The products cover all needs of cell expansion in academic research, pre-clinical research and cellular therapy. This ensures seamless transitions in regenerative medicine – from lab to patients in need. Our story goes back to 2015 and the idea to deliver animal component-free cell culture supplements. Today, we have changed the possibilities of cell expansion: Researchers switch from Fetal Bovine Serum to our animal suffering-free products. Stem Cell Therapy benefits the regeneration potential of our platelet-derived products. And we keep moving forward. Let's create the future of cell expansion together and join us on our mission.

Haifa, Israel

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production.

Haifa, Israel

Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.

Seattle, Washington, United States

Pluristyx is a pioneering company at the forefront of stem cell technologies. With a mission to revolutionize the field of regenerative medicine, Pluristyx develops innovative solutions that empower breakthroughs in stem cell therapies. The company's proprietary platform, panCELLa, represents a transformative leap in stem cell research, offering enhanced freedom to operate and unparalleled potential for medical advancements at a significantly accelerated timeline. Operating from two cutting-edge North American sites, Pluristyx is dedicated to driving progress and innovation in the realm of stem cell therapies. In July of 2023 Pluristyx and panCELLa merged. Pluristyx offers a portfolio of iPSC-based products and services to provide end-to-end client support in early product development, while panCELLa offers an array of unique and effective technologies with particular strength in gene editing. As one company, Pluristyx and panCELLa offer an enlarged portfolio whose long-term focus is to become the global leader in clinical-grade, genetically modified, “off-the-shelf” iPSCs with the lowest barrier to entry for cell therapy development, providing clients with the fastest speed to clinic and the best route to commercialization.

Carlsbad, California, United States

Predictive Biologybrings together stem cell biology, high throughput screening and genetics to elucidate molecular mechanisms underlying compound response.

Shenzhen, China

Shenzhen Pregin Biopharmaceutical Co., Ltd. is a national high-tech enterprise, Guangdong Provincial Cell and Gene Therapy Innovative Drug Engineering Technology Research Center, and Shenzhen Special New Enterprise. Investor shareholders include the National Small and Medium Enterprises Development Fund and the National Science and Technology Commission of the Chinese Academy of Sciences. Jiahe Fund, Haier Capital, Shenzhen Capital Group, Winbond Health ( 002004), etc. It has been deeply involved in the field of cell and gene therapy drugs for many years.

Sofia City, Bulgaria

Printivo is startup company operating in the field of Biotechnology. Currently we are situated in Sofia, Bulgaria. Our motto – “We print life” is the quintessence of our main goal namely to fabricate and design native-like human tissues and organs. Our inspiration is driven by the huge necessity of finding solutions for the growing humanitarian problem with shortage of organ transplants. Hundreds of people die each day, in this very minute in fact, failing to receive organ transplantation. This life-giving act must be accessible and affordable to each person and we are ready to take this difficult, uncertain and long way to fulfill their needs.

Saint Louis, France

Priothera - We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Marietta, Ohio, United States

ProtoKinetix (PKTX) is a research and development company leading the way in cell survival solutions. Its patented anti-aging glycopeptide (AAGP) is a revolutionary discovery with incredible opportunity to shape the future of ophthalmology, dermatology, transplant support and biomanufacturing. Based on a molecule found in nature and harnessed by a world-class research team, this anti-aging glycopeptide helps more cells survive longer and has the capability to change health care forever. With AAGP, health therapies will become more effective, more affordable and more accessible. We will get closer to cures for conditions such as Type 1 diabetes, macular degeneration, heart disease and stroke. More lives will improve, and more people will get the treatments they deserve. ProtoKinetix has harnessed a molecule found in nature with the power to transform lives and the future of health care. Founded in 2002, ProtoKinetix secured a patent for anti-aging glycopeptide (AAGP), a naturally-occurring molecule that regenerates cells for animals surviving in arctic temperatures. AAGP has gone through a series of tests in laboratories throughout Europe and North America conducted by some of the best researchers in the world. Backed by a decade of promising clinical research, all trials to date have shown that AAGP is safe, stable and effective in protecting and regenerating cells. This molecule could be the link to improved treatments for transplants, Type 1 diabetes, macular degeneration, stroke, heart disease and so much more. There is endless potential, and we’ve only seen the tip of the iceberg. Become part of the next great medical discovery.

770 Osterman Drive; Unit B; Bozeman, MT 59715; United States

PurCell Bio is an innovative cell culture research company located in Bozeman, MT. We have developed a line of cell culture media and media supplements that surpass the growth performance of serum and Essential 8. Our products solve many of the major problems associated with serum use, like batch to batch variability, contamination concerns, and high cost. For more information, please visit our website. Our vision is that PurCell's products will initiate an industry-wide exodus from animal-based products to chemically-defined alternatives. This shift will remove tremendous barriers for cellular-based therapies entering clinical trials and facilitate more effective research around the world.

Salt Lake City, Utah

Q Therapeutics is a biotechnology company based out of 417 S Wakara Way, Salt Lake City, UT, United States.

Encinitas, California, United States

At Reagents Direct, it is our mission to make quality reagents easily accessible to your lab. Reagents Direct is a small company that focuses our attention on you. We search for the important and upcoming reagents in the fields of cell biology, stem cell biology and biochemistry and get them directly to you as fast as possible. We take the effort out of searching for the best-priced reagent and show you all your options. Our mission is to bring quality reagents to our customers, when they want them. Once you get our reagents in your lab, we provide in-depth information on our product specification sheets, as well as detailed information on our website. We provide usage information, publications and insider tips from other scientists using our products. Reagents Direct should be your one stop to find all the information you need in order to use our reagents in your lab.

Osaka, Japan

Based on the discovery by our Founder, Professor Shimon Sakaguchi, we are developing stable, functional-induced Tregs that are antigen-specific (S/F-iTregs). Our S/F-iTregs address the limitations of earlier attempts to create therapeutic Tregs and competitive advantages over CAR-Treg approaches.

La Mesa, California, United States

Regen BioPharma Inc. is a publicly traded biotechnology company focused on developing innovative treatments using autologous cell therapies, RNA and DNA-based immunotherapy and small molecules in the immune-oncology and autoimmune disease space.

San Diego, California, United States

High-Throughput Screening Platforms

46-29 Yoshidashimoadachi-cho, Sakyo-ku, Med-Pharm Collaboration bldg. Kyoto University, Kyoto, Kyoto 606-8501, JP

Rege Nephro is a clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD) and small molecule for autosomal dominant polycystic kidney disease (ADPKD), and founded in 2019. There are 13 million patients with CKD in Japan, of which 340,000 are severe CKD patients forced to undergo artificial dialysis. The healthcare cost of dialysis is $12 billion, 4% of the total healthcare cost of Japan. However, there is still no curative treatment for CKD. Rege Nephro tries to treat patients suffering from CKD with cell therapy using nephron progenitor cells differentiated from iPS cells.

Portola Valley, California, United States

Regenerative Patch Technologies LLC (RPT) is a CA-based biotechnology company focused on the development of stem cell-based therapies designed to reverse blindness caused by advanced dry age related macular degeneration (AMD).

North Attleborough, Massachusetts, United States

Regeneris Medical is a healthcare and clinical research organization specializing in regenerative medicine and cellular therapies. We are driven by our mission to transform people’s lives by providing tomorrow’s healthcare today. Currently, research-level therapies such as PRP (Platelet Rich Plasma) and SVF (Stromal Vascular Fraction) are used to treat a variety of medical and aesthetic conditions including hair loss, arthritis, spine disease, joint pain, lupus, interstitial cystitis, multiple sclerosis, muscular dystrophy, ALS, Parkinson’s disease and stroke recovery.

25 Bridge Street, Pymble, New South Wales 2073, AU

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue regeneration applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Little Falls, New Jersey, United States

Welcome to Regenicin specializing development regenerative cell therapies, NovaDerm®

115 West Century Road, Paramus, NJ 07652-1407, US

Collagen Matrix is now Regenity Biosciences. Regenity Biosciences advances new frontiers in regenerative science, turning bioabsorbable materials into life-changing solutions. Sought after for our novel resorbable technologies and distinct approach to contract manufacturing and contract development, our team brings the urgency and vision to deliver breakthrough medtech solutions for medical technology and medical device manufacturers of all sizes. Company Background For more than 25 years, Regenity Biosciences has been transforming bioabsorbable materials into regenerative solutions to repair and regenerate tissue and bone we have since introduced numerous bioresorbable technologies with more than 71 product lines commercially available worldwide. Most recently, Regenity expanded its product portfolio to include versatile bioresorbable polymer technologies via the acquisition of Polyganics, which was the impetus behind the new name and brand direction. Regenity is headquartered in Paramus, New Jersey, with manufacturing locations in Oakland and Allendale, New Jersey and Groningen, the Netherlands. Mission & Values Every day, we work to make a material difference in the lives of patients. With people’s health on the line, it’s our duty to act with urgency and diligence. It is this collective ethos that drives us each day to push the boundaries of what’s possible in tissue repair and regeneration. Looking for a Career with Purpose? Join our team and work with us to develop life-changing products that help patients heal. Visit our website to learn more about what sets Regenity apart. www.Regenity.com CMIContact@CollagenMatrix.com

London, England

Bridgend, Wales, United Kingdom

Our focus at ReNeuron is on our CustomEx exosome technology platform, producing exosomes with unique tissue targeting tropisms to deliver a payload of choice to a preferred cell type. Our mission is to partner and develop novel exosome therapeutics for diseases with significant unmet needs.

Los Angeles, California, United States

Renovaro Biosciences, Inc. is a biotechnology company committed to developing advanced allogenic cell and gene therapies to promote stronger immune system responses potentially for long-term or life-long cancer remission in some of the deadliest cancers, and potentially to treat or cure serious infectious diseases such as HIV and Hepatitis B virus (HBV) infection.

4001 Millender Mill Rd, Reisterstown, Maryland 21136, US

RenOVAte Biosciences Inc (RBI) is a Delaware Incorporated, Maryland based animal biotechnology company founded in December 2016. RBI is in the business of performing sophisticated and precision genome editing and genetic engineering in livestock species, to address critical priorities of animal and human health.

Göttingen, Germany

Repairon's mission is the development, the manufacturing and the commercialization of induced pluripotent stem cell (iPSC) based tissues for organ repair. Our lead product are contractile heart tissue patches – Engineered Human Myocardium (EHM) – for the treatment of patients with advanced heart failure.

San Diego, California, United States

Replay is a genome writing company, which aims to define the future of genomic medicine through reprogramming biology by writing and reprogramming biology.

Vancouver, Canada

RepliCel Life Sciences Inc. is leading a revolution in the development of products for sports medicine and aesthetics. We are a regenerative medicine company developing innovative, clinical-stage technologies for unparalleled skin rejuvenation, tendon regeneration, and hair regrowth. RepliCel is currently involved in three clinical development programs: RCT-01 for treatment of Achilles tendinosis, RCS-01 for skin rejuvenation, and RCH-01 for treatment of Androgenic Alopecia. In Asia, RCH-01 is the subject of a co-development partnership with cosmetics and skincare giant Shiseido Company, Limited. Shiseido is currently funding a clinical study for the treatment of male and female pattern baldness (androgenic alopecia) in Japan with data anticipated in late 2018. RepliCel's nearest-term commercial asset is its next-generation dermal injector, RCI-02 which represents a medical device bringing unparalleled precision and consistency to dermal injections including shallow, even dispersion of dermal fillers for fine wrinkles. RCI-02 also promises to obviate the need for local anesthetic injections due to its patented skin-numbing element embedded in the device.

8F KDX Shin-Yokohama 381 Bldg., 3-8-11,Shin-Yokohama, Kohoku-ku, Yokohama, 222-0033, JP

REPROCELL supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and human tissue testing (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents, and iPSC-derived cell types (Stemgent). With our deep knowledge of stem cell biology, bioengineered (3D) tissue models (Alvetex) cell differentiation, and pharmacology, REPROCELL is a recognized leader in cutting-edge tools and services to accelerate regenerative medicine and drug development. The newly formed REPROCELL Medical business unit is developing a suite of reagents and services to meet the growing need for clinical-grade products and services that are appropriate for regenerative medicine. In addition, our labs offer diagnostic services for a variety of tests related to tissue compatibility and other biomarkers. And finally, REPROCELL also offers a GMP iPSC master cell bank manufacturing service. *** REPROCELL went public on the Japan JASDAQ in June 2013. Stemgent, BioServe and Reinnervate became parts of REPROCELL in 2014. Biopta was then acquired in 2015.

Redwood City, California, United States

Aspiring to add 10 years to healthy human lifespan, starting with cellular reprogramming, autophagy, & plasma-inspired therapeutics

6645 nancy ridge dr, san diego, california, united states, 92121-2253

Aye, Luxemburg, Belgium

RevaTis and University of Liège have developed and patented a specific procedure for the collection, production and storage of autologous muscle-derived mesenchymal stem cells (MdMSC) for immediate therapeutic use or storage for further processing. RevaTis technology is minimally invasive and offers benefits for generating a large number of autologous stem cells. Our sustainable avantages: - patents granted for obtaining pluripotent stem cells by a minimally invasive method for human and veterinary medicine - GMP production in aseptic isolator - Authorization for the production of batches in veterinary and human medicine for clinical studies or research - Accredited stem cell tissue-banks Our Market: The global market for stem cell treatments in animals has a growing rate annual average of 37.27% between 2017 and 2025 and will reach more than 200.000.000 €. In 2017, the global market for equine-level cell therapy was estimated at one third of the global market, In Human Medicine, RevaTis will focuse on the segment "Stem Cell Research and Services. This segment was $ 1,300 million in 2017 to arrive at a size estimate of market of $ 2,400 million in 2022. Our customers: In Vet Medicine, after the approval by agencies, our potential customer are the veterinarians. For Human Application, our markets include partners involved in - R&D Programs on Regenerative Medicine and Cell Therapy - Tissu engineering and 3D-Bio-Printing - Organ on a chip technology. In other words, all companies or Resarch Centers looking for a sourcing of large quantities of MSCs easily to transer in clinic.

New York, New York, United States of America

Rocket Pharmaceuticals (NASDAQ: RCKT), Ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. We are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based and adeno-associated virus (AAV) therapy approach. We have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. Ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need.

Olathe, Kansas, United States

Ronawk's Bio Block Universe is the first expandable Bio Platform from which other applications, processes, and technologies are developed. Ronawk's Bio Block Universe accelerates time to result by eliminating the need for sub-culture in cell production which subsequently decreases contamination risks and increases cell yield. Ronawk's Bio Block Universe transforms what was once tedious to effortless by simplifying cell culture workflows through the reduction of labor, materials, and space. Ronawk's Bio Block Universe increases biological opportunities by recapitulating the native cell environment to maintain cell viability, key characteristics, and secretion of therapeutic biologics.

Frederick, Maryland, United States

RoosterBio accelerates human mesenchymal stem/stromal cell (hMSC) and exosome/extracellular vesicle (EV) product and process development to fuel the rapid implementation of scalable advanced therapies. Our high-quality hMSCs, bioprocess media, genetic engineering tools, and exosome production solutions are paired with expert bioprocessing knowledge to progress therapeutic developers from concept to first-in-human testing and commercial manufacturing at reduced cost and increased productivity. With optimized, scalable processes, Type II Drug Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under one year. RoosterBio is driven by our client's success and creating a world where safe and effective advanced therapies are rapidly developed and widely available on a global scale.

Nine Edinburgh BioQuarter, 9 Little France Road, Edinburgh, EH16 4UX, GB

RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the groundbreaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones, including being among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR-edited stem cell-based therapy for a major disease to marketing authorization. Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialization and deliver life-saving Cell and Gene Therapies worldwide. Discover more about our services at www.roslinct.com.

310 E 67th Street, Suite 127

Rumi Scientific is a research-driven company focused on the discovery of drugs and innovative treatments for human genetic diseases. The company's mission is to fast-track the early stage of drug discovery using predictive models of the human brain for therapeutic success.

1389 Center Drive Suite 200, Park City, UT

RxCell is a biotechnology company that specializes in the development of advanced cell-based therapies for the treatment of various diseases and medical conditions.

316 huntington avenue, boston, massachusetts, united states

Safi Biotherapeutics is an early stage biotech company developing cell therapies from hematopoietic progenitor sources.

Boston, Massachusetts, United States

Samsara Therapeutics, Inc. is biopharmaceutical company aiming to discover first-in-class therapeutics that treat rare genetic and neurodegenerative disease, and extend healthy lifespan. Samsara's platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that enhance autophagy. Samsara Therapeutics is a global biotech company with operations in Oxford and Boston and significant academic collaborations in Paris and Graz

Seattle, Washington, United States

Sana Biotechnology is focused on utilizing engineered cells as medicines for patients. The ability to modify genes and use cells as medicines will be one of the most important advances in healthcare over the next several decades. Sana is building differentiated capabilities across the spectrum of cell and gene therapy. Three aspirations drive Sana as we look to discover treatments for patients with poor outcomes or currently untreatable diseases. The first is the ability to repair and control the genes in any cell in the body. We are advancing novel delivery technologies with the goal of being able to deliver any payload to any cell in a specific, predictable, and repeatable manner, paving the way for next-generation in vivo gene therapy. Next is the ability to differentiate pluripotent stem cells ex vivo into immune-cloaked functional cells with the aspiration of being able to replace any missing or damaged cells in the body. Last is a belief we can enable broader access to our therapies through focusing on scalable manufacturing solutions, the cost of manufacturing, and aligning with key stakeholders. Sana launched in early 2019 and has over 350 employees in Seattle, Cambridge, and South San Francisco. Sana was founded with the long view – bringing together great people and the best technologies to deliver on the challenging promise of using engineered cells to meaningfully change the outcome of many human diseases.

Mountain View, California, United States

SanBio, Inc. - Founded in February 2001 SanBio's scope of business is development, production and sales of regenerative cell medicines. Our mission is to develop regenerative medicines, creating benefits for patients and value for stakeholders. Our vision is to achieve global leadership in the regenerative medicine field using best science and technology, building global revenues and sponsoring successful clinical trials. SanBio focuses on using regenerative cell medicine to treat the disabilies caused by diseases of the central nervous system. Most of these conditions currently have no effective medicinal treatment, and those treatment that do exist generally address disease symptoms and not the underlying cause of the disease. Such conditions afflict a vast number of patients worldwide.As of January, 2016, SanBio had introduced a product for the treatment of chronic motor impairment from ischemic stroke and traumatic brain injury into clinical development in both Japan and the US. In the future, SanBio plans to continue expanding the indications and geographical regions for its products, using both internal development, as well as partnerships and licenses.

La Jolla, California, United States

Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding basic human biology and disease and advancing scientific discoveries to profoundly impact human health. Our track record of pioneering research spans more than 40 years and has produced breakthroughs in cancer, neuroscience, immunology and children's diseases and is anchored by our NCI-designated Cancer Center. Sanford Burnham Prebys' drug discovery center and global partnerships propel our prototype drugs and therapeutic strategies toward improving human health. A deep culture of collaboration and commitment to educating the next generation of scientists unites Sanford Burnham Prebys researchers, partners and philanthropists in a shared mission to improve human health.

Tampa, Florida, United States of America

San Rocco Therapeutics is a biotechnology company with its primary focus on curative gene therapies for Sickle Cell Disease and Thalassemia

Carlsbad, California, United States

ScienCell Research Laboratories is an expanding biotechnology company established in 1999. Our mission is to research and develop cell products for experimental and therapeutic use. ScienCell provides a variety of high quality normal human and animal cells, cell culture media and reagents, gene analysis tools, cell-derived molecular biology products, cell-based assay kits, and stem cell products for the research community. To complement our vast array of primary human and animal cells, we offer specialty medium designed to selectively promote unique cell growth, including STEMium™, which allows for the optimal growth of human pluripotent stem cells under feeder-free conditions. The Scientists at ScienCell are studying and developing cell therapeutic strategies to significantly improve the quality of life for patients with degenerative diseases.

Germantown, Maryland, United States

Seraxis is a privately owned biotechnology company. Our GMP lab is located in Germantown, Maryland, in the heart of the vibrant BioHealth Capital Region. Launched in early 2013, Seraxis used proprietary technologies to develop a cell replacement therapy, SR-01, that is more effective and safer than embryonic stem cell-derived therapies. Our highly pure insulin-producing cells are micro-encapsulated through a proprietary technology that enables the function of human pancreas cells in type-1 diabetes models without the need for immuno-suppression. Seraxis intends to bring SR-01 to the clinic in order to provide a cure for the devastating disease of diabetes.

Cambridge, United Kingdom

Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of aging. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high throughput and high accuracy aging biomarker, which has been leveraged inside AI-based cell simulations to identify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes the norm.

South San Francisco, CA, USA

Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.

La Jolla, California, United States

Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.

Cambridge, Massachusetts, United States

Simnova is a clinical stage biotech company focusing on the development of first/best-in-class cell therapy for cancer treatment.

Singapore, Singapore

SABio is a biotechnology company that offers quality custom-made RNA oligos/siRNAs, peptides, ready-made antibodies, custom antibody production services, and more.

Sydney, New South Wales, Australia

S2N’s vision is a world where neuronal loss no longer means loss. Our regenerative medicine technology starts with the human hair follicle and ends with production of millions of pure neurons, all gene modification free. We aim to transform health, science and society.

Tullinge, Stockholm, Sweden

SmartCella, founded in 2014, is an innovative biotechnology and medtech company based in Stockholm, Sweden. SmartCella’s vision is to combine first-in-class delivery platforms with cutting-edge cell and gene therapies to unleash the full potential of targeted therapies. The company has three main business units, Smartwise, SmartCella Solutions and Procella. Smartwise is developing and manufacturing a first-in-class endovascular delivery device, the Extroducer, that enables direct tissue/organ infusions through the vessel wall directly into to hard-to-reach organs and tumors. There is a significant unmet need in the field of targeted delivery of different types of therapies for regeneration of tissue and for treatment of cancer tumors. Smartwise received regulatory approval from the US FDA for the Extroducer in June 2022 and is now actively out-licensing the technology to global companies with therapies that benefit from direct delivery. SmartCella Solutions create novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs or microenvironments. A pipeline of projects within regeneration and tolerization, focusing on oncology, is in pre-clinical development. Procella has advanced capabilities within stem cell therapy development and inhouse cGMP manufacturing of cell based therapies, with a proven platform to take stem cell projects from discovery phase to clinical development. A globally licensed cardiac stem cell therapy is entering clinical stages (in collaboration with AstraZeneca) and there is a growing pipeline of projects in different stages of development, with dopamine producing cells for Parkinson´s Disease and our own iMSCs most advanced.

Paris, Île-de-France, France

Smart Immune is a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, enabling next-generation allogeneic T-cell therapies for all. The company is a spin-off from the Imagine Institute of Genetic Diseases, and was founded in 2017 by Karine Rossignol, PharmD-HEC, Marina Cavazzana, MD-PhD and Isabelle André, PhD to transform outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has clinical partnerships with leading institutions in the US and Europe. The ProTcell platform, already in Phase I/II clinical trials, enables the accelerated recovery of a complete immune repertoire in patients fighting cancer and infection. The ProTcell platform introduces potent, allogeneic T-cell progenitors which are then differentiated by the thymus into fully functional T-cells, to ultimately develop an ‘off the shelf’ T-cell medicine. The company is headquartered in Paris, France, at Paris Biotech Santé.

zürich, zurich, switzerland

Somagenetix is a new company that aims at becoming a leading gene therapy company with first-in-class treatment for phagocyte-related disorders. We are spin-off from the University of Zurich and we are leveraging world-class scientific and clinical expertise to solve unmet medical needs through gene therapy. Carried by a highly experienced scientific team with over 17 years experience in gene therapy research, clinical development and applications, our mission is to cure all patients with Phagocyte Disorders. A cutting-edge technology with a complete & unique platform solving all challenges of ex-vivo gene therapies: specificity, long-term efficacy and safety. Our goal is to cure patients with immunodeficiency, neurodegeneration and cancer with brain metastasis via genetically enhanced phagocytes.

1100, boul. René-Lévesque Ouest, 25e étage, Montréal, QC H3B 5C9, CA

Starpax Biopharma Inc. has developed a novel Precision 3D Guidance Therapy of Magnetodrones™ in tumors. Magnetodrones™ are unique medication-bearing bacteria, developed by Starpax™, that are sensitive to magnetic fields. They deliver the medication into the mass of the tumour, without allowing the medication to circulate in the bloodstream. At the same time, the Magnetodrones™ saturate hypoxic areas where cancerous cells are difficult to reach with other treatments. Magnetodrones are injected directly into the tumour and are guided by the PolarTrak device, in which the patient is positioned. The PolarTrak™ prevents the Magnetodrones™ from leaving the tumour and guides them in 3D with special magnetic fields. Starpax Biopharma inc. a développé une thérapie inédite de guidage de précision 3D de Magnétodrones™ dans les tumeurs.. Les Magnétodrones™ sont des bactéries uniques développées par Starpax, sensibles aux champs magnétiques, sur lesquelles sont attachés les médicaments à leur surface. Les Magnétodrones™ distribuent des médicaments dans la masse des tumeurs sans circuler dans le réseau sanguin, tout en saturant les zones hypoxiques où les cellules cancéreuses sont difficiles à atteindre par le biais d'autres traitements. Les Magnétodrones™ sont injectés directement dans la tumeur et guidés par l'appareil PolarTrak™, où le patient est installé. Le PolarTrak™ empêche les Magnétodrones™ de sortir de la tumeur et les guide en 3D grâce à ses champs magnétiques spéciaux.

New York, United States

Stelexis is a Deerfield founded and solely funded New York-based cancer therapeutics company with a mission of transforming cancer therapeutics paradigm and patient care, through the discovery and development of novel drugs. Stelexis proprietary platform is focused on identifying, isolating and studying the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations, that drive the formation of primary and recurrent human tumors. Stelexis utilizes this powerful platform as a target identification engine and drug discovery and development tool to address unmet needs in multiple cancer indications. Deerfield founded Stelexis Therapeutics in 2017 together with scientific founders, Drs. Ulrich Steidl, Evripidis Gavathiotis, Amit Verma and Roman Perez-Soler of Albert Einstein College of Medicine, Montefiore Medicine, New York and Dr. Derrick Rossi of Boston Children’s Hospital, Harvard Medical School.

San Antonio, Texas, United States

StemBioSys is located in San Antonio, Texas and proximate to the University of Texas Health Science Center San Antonio (UTHSC-SA) from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth and delivery of stem cells or other difficult to culture cells for research, diagnostic and therapeutic applications. We are currently focused on scale-up activities for our patented core technology, CELLvo™ Matrix and our initial product launch to the stem cell research market in mid-2015. Build-out of our cGMP facility with partner BioBridge Global is complete and we have begun to explore therapeutic applications and business relationships with potential partners for other, next generation, product offerings from this versatile platform technology. Our core novel technology platform is an advanced stem cell culture system – CELLvo™ Matrix. CELLvo Matrix™ replicates the 3-dimensional “home” in which stem cells naturally reside and proliferate. Stem cells grown in BM-HPME™ remain small, proliferative and undifferentiated. Our unique technology enables users to isolate and grow stem cells and other difficult to culture cells from a variety of sources including but not limited to adipose, bone marrow and umbilical cord blood/tissue and cancer cells. Stem cells are the future of medicine. We are the future of stem cells. We will build value for our shareholders by perfecting and focusing on the use of our disruptive stem cell technology platforms, know-how and intellectual property for the treatment of meaningful medical disorders. We will establish the facilities, expertise, discipline and culture required to assure our patients, physicians, researchers and partners that everything we do will conform to the highest standards of quality.

Cambridge, Massachusetts, United States

StemCellerant designs and manufactures stem cell based research tools and therapeutics with a mission to accelerate personalized regenerative medicine.

Vilnius, Lithuania

UAB "KAMIENINIŲ LĄSTELIŲ TYRIMŲ CENTRAS" is a stem cell research company that focuses on promoting innovative discoveries and translational research through clinical research and bioprocess engineering.

Vancouver, Canada

STEMCELL Technologies is a Canadian biotechnology company that helps power leading-edge life science research around the world. Driven by our love of science and passion for quality, we are Scientists Helping Scientists—standing by our customers to provide the outstanding products, technical support, and training they need to advance their research. Scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research are among those who rely on our cell culture media, cell separation products, instruments, accessory products, and services. Since the launch of the company by Dr. Allen Eaves in 1993, STEMCELL has reinvested all profits back into the research and development of products to better support the international research community. Today, STEMCELL is the largest biotech company in Canada, with over 2000 employees globally, most with scientific or engineering degrees. Through our many regional offices, as well as our distribution centers in Vancouver, Seattle, Grenoble, and Singapore, we deliver our innovative, specialized products to more than 70 countries. At STEMCELL, we are dedicated to improving lives through advancing knowledge and scientific discovery, through our commitment to fostering diversity and inclusion in STEM and the life sciences industry, and through our investments in sustainability, community, and social responsibility. We do all this because we love science as much as you do. #ScientistsHelpingScientists

13800 live oak ave, baldwin park, california, united states

San Diego, California, United States

Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company's lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of ischemic stroke and Alzheimer’s disease. The company’s second drug candidate, ischemia-tolerant neural progenitor cells, or itNSCs, is an allogeneic cell therapy currently in development for spinal cord injury. In addition, Stemedica is developing progenitor multi-cell therapy (itMSCs and itNSCs) for ischemic stroke and progenitor cell and protein combination therapy for Alzheimer’s disease. More information on Stemedica may be found at www.stemedica.com.

Piazza della Scienza, 2 Milano, 20126

StemGen is a clinical stage biotech company developing innovative differentiation biotherapies for cancer. StemGen is also involved in research on neural stem cells.

Delhi, India

StemGenn Therapeutics is leading the research and Development of efficient and affordable Cell Therapy ,Preventive & Personalized Functional Medicine for a wide range of Metabolic, Auto immune & Lifestyle conditions . StemGenn Aiming for Develop personalised Products for Cosmetic Gynecology, Infertility & Aesthetic Medicine. StemGenn Provides Personalized Care for Men’s Health for their Complete care from Skin, Diet to Sexual Health( Erectile Dysfunction). StemGenn Started exclusive Training Program to doctors , scientists and researchers for Regenerative Medicine, PRP, Cosmetic Gynecology( Vulvo-Vaginal Rejuvenation), Aesthetic Medicine, Laser, Radio Frequency and Bio-Revitalisation techniques first time in India . Stemgenn’s vision is to create a better and healthy world with cellular therapies and regenerative medicines. We aim at leveraging the benefits of stem cell therapy for anti-aging. Our core values consist of Caring, Safety, Excellence and Integrity for creating a healthy tomorrow."​ Mission: Contribute to human health by enabling technologies using Regenerative Medicine. Training programs are developed by our scientists and team of clinicians with the aim to overcome challenges in your experimental/ clinical procedures and advance your research and Therapeutics.We are Scientists Helping Scientists and doctors .Our highly interactive technical training is current with the latest tools and protocols, designed specifically for your needs. Contact : +91 9811011690, Email: contact@stemgenn.com

Taipei, Taiwan

Steminent Biotherapeutics Inc. is the leading stem cell clinical development company in Taipei, with subsidiaries in San Diego and Shanghai, dedicated to the development of novel cellular therapeutics for the treatment of diseases with unmet or under-served medical needs. Steminent utilizes advanced, proprietary processes and know how to isolate, purify, amplify and manufacture standardized stem cell products of the highest quality for research and clinical development in multiple indications. Steminent’s Stemchymal® allogeneic cell therapy R&D program has generated a portfolio of clinical stage therapeutic candidates for multiple diseases including: Phase II; Spinocerebellar Ataxia (PolyQ SCA), Phase I; Osteoarthritis of the Knee, and Phase I: Acute Liver Failure. 幹細胞醫藥產業先驅的仲恩生醫，以推動異體間葉幹細胞治療為核心，擁有世界一流的幹細胞研發團隊與技術。獨家核心技術平台Stemchymal®，以領先全球的幹細胞分離、純化、增生技術，應用於自體及異體的脂肪間葉幹細胞治療。 仲恩生醫以最嚴謹的製藥規範與品質管理，不斷累積科學實證，並透過國內外頂尖醫學中心臨床試驗證實仲恩生醫幹細胞產品的安全與療效。除此，仲恩生醫透過與臨床醫師及國內外合作夥伴緊密的合作，持續地針對臨床未被滿足的需求，持續開發Stemchymal®優質細胞產品於急性肝衰竭及其他適應症之應用，期許未來多國的二期臨床試驗的結果，以及在其他不治和難治病症上的努力和不斷的進步，將可盡早實現幹細胞藥物在臨床應用的價值，嘉惠無藥可醫之病患。 2016年藉由台日再生醫療的策略結盟，深化台日雙方的合作關係，更促進再生醫學產業化和實用化的發展。2018年向美日兩國申請的臨床試驗二期申請案，相繼於7月14日和7月29日正式通過。一旦於日本完成異體間葉幹細胞新藥的二期臨床試驗，將依日本再生醫藥專法申請孤兒藥資格及最高7至10年暫時性藥證許可。

Bangalore, Karnataka, India

Stempeutics is a leading Regenerative Medicine company in Bangalore with our patented stem-cell therapy platform technology developing treatment of cardiovascular, immune-mediated and degenerative diseases. The company's flagship product, Stempeucel® has received market authorization to treat Critical Limb Ischemia – a major unmet medical need in India. It is the FIRST innovative cell therapy based product to get marketing approval in India and Globally. CIPLA, the Indian licensee, has commenced pan-India commercialization. It has the FIRST DCGI approved Cell therapy product for Knee Osteoarthritis being marketed by Alkem. Stempeutics has a product in the Phase 3 stage covering Diabetic Foot Ulcer. Further it is conducting Phase 2 trial in Perianal fistula due to Crohn’s disease. Stempeucel® has strong patent protection with 20 patents granted including US, Europe and Japan. Stempeucel® has been classified as an Advanced Therapy Medicinal Product (ATMP) and designated as an Orphan Drug for the treatment of CLI due to Buerger’s Disease by the European Medicines Agency (EMA) Another portfolio developed by Stempeutics is Stempeucare® range of cosmetics. It is developed from the stem cell derived Growth Factors/Cytokines combination for various cosmetic and derma applications including rejuvenation of aging skin, hair fall control & hair growth promotion, under eye dark circle reduction cream etc. First product which has gone to the market is an intensive firming skin care cosmetic product, branded as Cutisera™. Other products ready for marketing are Trichosera™ for Hair application and Optisera™ for under eye application With a strong pipeline in Cell and Gene therapy products in some of the largest health and personal care segments like OTC Cosmetics (Skin and Hair Care), Osteoarthritis, Diabetes, CLI and PAF Stempeutics is poised to transform the Cell & Gene therapy space with its India First, Global Next approach.

Tampere, Finland

StemSight develops off-the-shelf regenerative cell therapies for corneal blindness. Our expertise is in the combination of iPS-derived cells with functional biomaterials - for FASTER tissue regeneration, SAFER cell therapies and EASIER cell delivery.

San Diego, California, United States

At Stemson Therapeutics, we envision a world where anyone battling the emotional trauma or social stigma of hair loss has an opportunity to truly cure their condition and safely restore their natural hair.

copenhagen, capital region of denmark, denmark

Liver disease kills approximately two million people per annum. Although organ transplant is a viable option to treat disease, many patients are not candidates for this type of treatment or die on the transplant waiting list. Stimuliver is developing a disruptive liver implant to treat critically failing liver function in humans. The implant will be placed underneath the skin to ‘top up' the patient's reduced liver function. Lab engineered liver tissue will be produced from human stem cells, providing a scalable and renewable source of human liver tissue. The development of the liver implant to clinical grade will provide patients with a renewable treatment option for their disease.

Superior, Colorado, United States

Sudhin Biopharma Co. is a biotechnology company developing efficient continuous biological manufacturing processes for therapeutic biologicals, sweet proteins, cell therapies and biological roducts.

Chicago, Illinois, United States

Sunny Biotechnology Co focuses on the development of polyclonal, monoclonal, secondary antibodies, serum-free media and supplements for stem cell research, peptide synthesis service, and related biotech products for life science research and clinical diagnosis.

Salt Lake City, Utah, United States

SymbioCellTech (SCT) is an early stage, university spin out, that has developed stem cell-based technology that achieves euglycemia (glucose control) in Type-1 Diabetes, and will soon be adapted for Type-2 Diabetes. The SCT proprietary Neo-Iset therapy, comprising both pancreatic islet and mesenchymal stem cells, can be administered in a simple out-patient procedure resulting in glucose control identical to that of a normal healthy individual. Backed by rigorous NIH, VA and privately funded research and resultant data, SCT has completed pre-clinical trials and is preparing for FDA submission and approval to begin well-designed, controlled, clinical trials treating humans suffering from Type-1 Diabetes. FDA Investigational New Animal Drug (INAD) approval for diabetic companion animals has been approved and canine clinical trials are ongoing with outstanding results and outcomes.

Chicago, IL, US

Syntax Bio is a preclinical-stage biotech company, overcoming longstanding challenges in stem cell-derived therapies by directly controlling and accelerating cell differentiation.

Mountain View, California, United States

At SBI, our mission is to accelerate your science by turning the latest insights and technologies into robust research products and services to advance exosome studies, biomarker research, gene delivery, SARS-CoV-2 studies, and more.

San Francisco, California, United States

Tachyon is accelerating innovative science to develop first-in-class therapeutics against significant new drug targets in cancer biology. Tachyon operates with a dedicated internal core development team and a world-class external network of expertise to achieve one goal - advance our programs with speed, innovation, quality and scientific integrity.

Buffalo, New York, United States

Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach.

jonas webb building, babraham research campus, cambridge, england, united kingdom

Talisman Therapeutics is a human stem cell drug discovery company, based in Cambridge, UK. We are committed to revolutionising the discovery of treatments for Alzheimer’s disease (AD). Our novel human stem cell models of AD provide a transformative platform for rapid and more therapeutically relevant compound identification, thereby offering the potential to significantly accelerate drug discovery and, more importantly, de-risk subsequent development.

Bothell, Washington, United States

The company is developing a ventricular shunt, for children with hydrocephalus.

Carlsbad, California, United States

Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzyme-based platform technologies and products to improve clinical efficacy and cost of care outcomes for cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene therapy and regenerative medicine. The Company’s clinical-grade fucosyltransferase enzymes and small molecule products (TZ101 and TZ102) are off-the-shelf biologic products used at the point-of-care to treat therapeutic cells immediately before infusion into the patient using a simple procedure that is easily incorporated into existing medical practice. The Company has received worldwide patents, multiple FDA orphan drug designations, has an open investigational new drug application (IND) with multiple ongoing clinical studies and a Phase 3 Special Protocol Assessment (SPA) with the FDA. Targazyme’s fucosylation technology has received numerous medical and scientific awards from institutions such as NIH, NCI, US Treasury, CPRIT, ETF, OCAST, JDRF, Leukemia, Lymphoma Society. Targazyme has partnerships and collaborations with Kyowa Hakko Kirin and Florida Biologix, as well as various medical research institutions including The University of Texas M.D. Anderson Cancer Center, Oklahoma Medical Research Foundation, Texas Transplant Institute, Case Western/University Hospitals, Scripps Hospitals, Fred Hutchinson Cancer Research Center, University of California Los Angeles Medical Center, Stanford University Medical Center, University of Minnesota Medical Center, University of California San Diego Medical Center, Sanford-Burnham Medical Research Institute, Indiana University, Memorial Sloan Kettering Cancer Center, and New York Blood Center. Learn more at http://www.targazyme.com.

Holytown, North Lanarkshire, Scotland, United Kingdom

TC BioPharm is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. We have a growing team based in our Glasgow office, alongside a wide range of scientific advisors, and partner organisations.

275 Shoreline Drive, Suite 325, Redwood City, California 94065, US

Telios Pharma, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, specializing in developing therapies for mast cell-mediated inflammatory diseases. Founded in 1993, the company focuses on small-molecule drugs and has a team of 51 to 100 employees. Its annual revenue is estimated between $10 million and $25 million. The company's pipeline includes innovative Bruton’s tyrosine kinase (BTK) inhibitors. Notable candidates are TL-925, a topical eye drop for dry eye disease currently in Phase 2 trials, and M-7583, an oral BTK inhibitor for primary myelofibrosis. TL-925 has shown promising results, providing rapid relief from symptoms and significant improvements in clinical measures. Telios Pharma aims to address significant unmet needs in both dry eye disease and myelofibrosis, targeting markets with limited existing therapies.

Baltimore, Maryland, United States

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on developing Telomir-1 as the first novel small molecule to lengthen telomeres, which are protective structures at the ends of chromosomes that play a key role in cellular aging and disease. The company is dedicated to the development and commercialization of therapeutic products for the treatment of age-related diseases and conditions.

San Francisco, California, United States

Tempo Bioscience is a biotechnology company that develops human stem cells based disease models and biosensor enabling technologies for various applications.

3030 Bunker Hill Street, Suite 104, San Diego, CA 92109

Tempo Therapeutics is a biotechnology company that specializes in tissue engineering using proprietary MAP material science technology to build functional tissue and organs within patients in real time for disease treatment.

South San Francisco, California, United States

Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was incorporated in 2016 and is based in South San Francisco, California.

London, United Kingdom

Tenpoint Therapeutics Limited is a global, clinical-stage biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy. Its lead asset, BRIMOCHOL PF, is a novel, pupil-modulating therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately 2 billion people globally. BRIMOCHOL PF has completed its first Phase 3 pivotal trial (BRIO-I) and will complete the second pivotal study, BRIO-II, in 2025. This topical ophthalmic is poised for launch in 2026. Tenpoint’s leadership team includes ophthalmic industry luminaries with track records of successful approvals and commercialization of blockbuster drugs. A privately held company, Tenpoint Therapeutics is backed by AdBio Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital, Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and UCL Technology Fund.

Blackburn, Australia

Tessara Therapeutics Pty Ltd is a regenerative medicine company developing RealBrain® technology to break therapeutic barriers in the biopharmaceutical industry. RealBrain® technology is based on human mimetic 3D neural micro-tissues designed to have high physiological relevance, manufactured at industrial scale for unprecedented reproducibility. Priority applications include a high-throughput drug screening platform that includes a range of models of healthy and diseased brain tissue, and a regenerative medicine platform to develop next generation safe and efficacious tissue therapies for significant unmet neurological medical needs.

Seoul, South Korea

Therabest is a biopharmaceutical company that develops iPSC-derived immune cells. Our mission is to provide the benefits of cell therapy to many patients. We established a robust process that manufacture Armored iPSC CAR-NK, off-the-shelf cell products using our exclusive technology. Currently, our main pipeline is CD19 (Lymphoid tumor) and Muc1c (Solid tumor). We plan to expand our pipeline through collaboration with companies that own tumor target scFv.

Oceanside, California, United States

Currently the Company is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. Activating one’s immune system is now an accepted method to treat certain cancers, reduce recovery time from viral or bacterial infections and to prevent illness. Additionally, inhibiting one’s immune system is vital for reducing inflammation, autoimmune disorders and allergic reactions. TSOI is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, and for daily health.

Waltham, Massachusetts, US

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Cambridge, Massachusetts, United States

Thymmune is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. The company's cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune diseases. Thymmune is based in Cambridge, MA.

Honolulu, Hawaii, United States

Adipose Cell Isolation

Carlsbad, California, United States

London, England, United Kingdom

We are developing cancer treatments that specifically target the cancer stem cell population in tumors. Targeting these cells will prevent relapse and disease progression leading to long-term patient benefit.

Philadelphia, Pennsylvania

Tolerance Bio will increase health span by preserving and restoring the function of the thymus, the master regulator of immune tolerance. Immune-mediated diseases represent a significant unmet medical challenge: cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies.

10000 Cedar Avenue , Cleveland, OH 44106, US

Trailhead Biosystems merges developmental biology and cell therapeutics with cutting edge hardware, and computerized experimental design and analysis to perform process-specific parameter optimization for customers seeking to develop cell therapies. Implementing Quality by Design (QbD) principles, cell culture optimization is done by utilizing Design of Experiment (DoE) theory combined with Multivariate Data Analysis (MVDA). This allows Trailhead to generate mathematical models of the biological system, understand the effector-response relationship in cell culture, and provide a systems biology analysis of the differentiation space. DoE-based experimental design and robotic execution greatly reduce the number of experiments and time needed for optimizing a large number of variables simultaneously. You will see that Trailhead Biosystems is novel from its ability to: Have computer-based experimental designs executed for advanced cell culture Gain knowledge into how cell culture affects gene expression in cells Mathematically model the effector/response space so virtual experiments can be performed and enable exploration of cell biology to predict how additives will create desirable cell culture fates Address optimization challenges for cell purity and potency Understand the variance in cell manufacturing methods

Plot No:70A/ B, Door No: 8293/ 82/2, Sri Venkateshwara, Road, No:12,, Banjara Hills, MLA Colony, Hyderabad, , Telangana 500034., IN

Transcell Biologics is an innovative biotech company with continuous discovery and process development as it's central theme to deliver unique disruptive stem cell based solutions to treat chronic and debilitating diseases that have otherwise no options available to manage. The passionate leadership team is committed to developing therapies to address important medical needs through adult stem cell technologies by collaborating with clinicians and patient communities. Among the company's landmark innovations is the development of a novel proprietary process for maximizing the therapeutic stem cell yield that also maintains the native pluripotent properties and inherent functionality. The Company has evolved from solely an R&D-focused biotech entity diversifying based on the intended applications of stem cell technologies.

Bordeaux, Aquitaine, France

TreeFrog Therapeutics is a French-based biotech company aiming to unlock access to cell therapies for millions of patients. TreeFrog Therapeutics is developing a pipeline of therapeutic candidates using proprietary C-Stem technology, allowing for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues with unprecedented scalability and cell quality. Bringing together over 150 biophysicists, cell biologists and bioproduction engineers, TreeFrog Therapeutics raised $82M in 2021 to advance its pipeline of stem cell-based therapies in the field of regenerative medicine with the lead program in Parkinson's Disease. In 2022, the company opened a technological hub in Boston, USA to drive the adoption of C-Stem and initiate co-development partnerships with leading academic, biotech and industry players in the field of cell therapy.

San Diego, California, United States

Trestle Biotherapeutics, Inc. is a preclinical stage company developing bioengineered therapies for patients living with end stage renal disease. Once implanted, these bioengineered stem cell-derived tissues will get patients off dialysis, delay their need for transplantation, and one day become replacement organs.

Mountain View, California, United States of America

We are a biotechnology company focused on restoring cells’ youthful vigor to repair damage caused by the aging process. Using a proprietary ERA™ Platform, we develop mRNA medicines that are specially formulated to instruct specific cells in the body to fight disease or repair damaged tissue. We do this by reprogramming the epigenome to restore cell function that people often lose as they age. This approach can be used to revitalize different cells throughout the body – we are researching its applicability across multiple therapeutic areas, including dermatologic conditions, immunology, osteoarthritis and ophthalmology.

Building 10 Cherrywood Business Park Cherrywood Loughlinstown, Co. Dublin

Ulysses Neuroscience Limited is an Irish Private R&D Organisation providing clinical and preclinical research services to pharmaceutical companies.

Silver Spring, Maryland, United States

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. We currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! Our employees can be found collaborating across the United States, Europe and Asia. As a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases.

Shanghai, China

Sunrise, Florida

U.S. Stem Cell, Inc. is a leader in regenerative medicine and is committed to providing autologous cell therapies for the treatment of degenerative conditions. The company specializes in the development of proprietary, physician-based stem cell therapies; novel regenerative solutions, including its lead product AdipoCell™; physician training and certification; veterinary applications; stem cell banking; as well as creating and managing new stem cell clinics. In the past 20 years, to the company’s knowledge, U.S. Stem Cell, Inc. has completed more clinical treatments than any other regenerative care provider in the world. With more than 700 physicians trained and certified with the company, U.S. Stem Cell, Inc. boasts the largest network of physicians working together to continue its mission of harnessing the body’s own ability to heal from within to treat a wide variety of conditions and to improve quality of life.

Sunrise, Florida, United States

U.S. Stem Cell, Inc. is a leader in regenerative medicine and is committed to providing autologous cell therapies for the treatment of degenerative conditions. The company specializes in the development of proprietary, physician-based stem cell therapies; novel regenerative solutions, including its lead product AdipoCell™; physician training and certification; veterinary applications; stem cell banking; as well as creating and managing new stem cell clinics. In the past 20 years, to the company’s knowledge, U.S. Stem Cell, Inc. has completed more clinical treatments than any other regenerative care provider in the world. With more than 700 physicians trained and certified with the company, U.S. Stem Cell, Inc. boasts the largest network of physicians working together to continue its mission of harnessing the body’s own ability to heal from within to treat a wide variety of conditions and to improve quality of life.

San Diego, California, United States

Vala Sciences helps researchers achieve an unrivaled in vitro understanding of how human cells respond to drug compounds. Vala is committed to providing expert services to pharmaceutical developers and researchers to help overcome the persistent challenge of reducing avoidable clinical failures of drug candidates in the following areas: Cardiac biology: By precisely measuring up to three channels (voltage, calcium, and contractility) of single-cell hiPSC-cardiomyocyte kinetic data in real time and comparing cell responses with known healthy or disease-model cells, Vala can help rank order drug candidates by identifying toxicities, dose response, and efficacy. Neuroscience: Vala has developed co-culture assays with hiPSC-neurons, -microglia, and -astrocytes for neurodegenerative disease drug discovery and toxicity screening. By measuring voltage and calcium kinetics, neurite and synapse formation, and engulfment by microglia, Vala can provide a detailed picture of disease mechanisms and treatment efficacy. Vala Sciences develops and manufactures the Kinetic Image Cytometer (KIC®) and Structured Illumination Microscopy (SIM) platforms, which enable information-rich measurements for making new insights into the cell biology of disease. CyteSeer®, our cell image analysis software, can resolve billions of single-cell data points from fixed or live cells. Vala’s toolset allows researchers to perform accurate, cost-effective screens for drug candidates with high probability of clinical success and low probability of side effects. We provide varied and validated high content screening services that quantify the effects of compound libraries on a number of target molecules. Vala is a registered supplier on Scientist.com. Visit our profile here: https://app.scientist.com/domain_switcher?redirect=/providers/vala-sciences

Chicago, Illinois, United States

Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).

Madison, Wisconsin, United States

Vascugen is dedicated to revolutionizing the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow, particularly for those patients at high risk for amputation and death for whom few to no treatment options remain. The company’s lead product is an allogeneic vasculogenic cell – a cell with the potential to forge new blood vessels in oxygen-starved tissues. The vasculogenic cell product is manufactured from induced pluripotent stem cells (iPSCs), which provide a limitless source from which to produce off-the-shelf, cryopreserved doses at scale.

Cambridge, Massachusetts

Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology. Our patented technology, called ARMMs (ARRDC1 Mediated Microvesicles), enables us to deliver a wide range of payloads, including RNAs (mRNA, shRNA, ribozymes), proteins (signaling proteins, enzymes, antibody fragments), and editing complexes (Cas9/gRNA) directly into the cytoplasm of target cells, expanding the universe of druggable targets. Our team is committed to leveraging ARMMs technology to enable new therapies and address currently unmet medical needs.

Poway, California, United States

VetStemprovides veterinarians and owners with a way to treat dogs, horses and cats with the animal's own stem cells.

Boston, Massachusetts, United States

Our Mission: To provide the highest-quality stem cell preservation service and care to our patients, families, and their physicians. We at ViaCord believe these words are much more than just a promise. They are the commitment we live by. Our Origins: ViaCord was established in 1993 to give expectant parents an opportunity to bank their children's cord blood with comfort and security. Prior to launching our Cord Blood Banking Service, ViaCord conducted extensive research and validation studies to set high standards regarding the collection, processing, and storage of cord blood. ViaCord worked closely with the following institutions during our development: * Obstetrics Program at Brigham and Women's Hospital in Boston, MA * The Christ Hospital in Cincinnati, OH * The University of Cincinnati's Hoxworth Blood Center, OH ViaCord's headquarters are located in Cambridge, Massachusetts; a recognized global hub of biotechnology. All cord blood collections are processed and stored at our cord blood storage facility outside of Cincinnati.

10918 Technology Pl, San Diego, California 92127, US

Visicell Medical Inc. was founded by a team of passionate scientist, engineer, and radiologist with a singular goal: to help accelerate stem cell-based therapy to the market for patients who are afflicted with devastating and currently incurable diseases. Our technology platform will transform how biopharmaceutical products are developed and taken to market by offering customers clinically applicable imaging tools that can provide real-time insights for their unique individual research needs.

South San Francisco, California, United States

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company’s CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company’s CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.

Baltimore, United States

Vita Therapeutics - We are a team of dedicated scientists striving to advance treatments in multiple indications in our cell therapy platform. Our mission is to utilize the power of genetics to deliver life-transformative cell therapies by unlocking the potential of engineered cellular medicine.

B-13, Mogappair Industrial Estate, Mogappair West, Chennai, Tamil Nadu 600 037, IN

Vopec Pharmaceuticals Private Ltd. is a pioneering company which is manufacturing Ayurveda and siddha formulations, and was established in the year 1996. Vopec pharma has taken up a leading role in the formulations re-establishing ancient knowledge with modern Research and manufacturing techniques. The company is located in Aminjikarai, Chennai having GMP Certificate and FSSA licence to manufacture nutraceuticals. Vopec also have licence to manufacture Ayurvedic and Siddha formulations including Sasthric products and Food supplements. Vopec is a stake holder in Traditional Ayush Cluster of Tamilnadu (P) Ltd., precisely called TACT. Vopec Pharmaceuticals has various herbal capsules, syrups and pain relieving oils like Nart Capsule, Asmask Capsules, Dyzee Syrup etc. Another exciting program that Vopec provides are the consultation slots with Ayurveda experts, where one can mention their problems or issues and get effective solutions within minutes.

Cambridge, Massachusetts, United States

We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies.

Madison, Wisconsin, US

As a recognized world leader in pluripotent stem cell banking and characterization, WiCell provides the stem cell community with high-quality cell lines as well as accurate and reliable cell characterization and cytogenetic testing services. We offer both cGMP and research grade services and cell lines to fit your lab's needs. In addition, WiCell offers affordable and reliable long-term LN2 storage through our WiCellSAFE program to safeguard and protect your research investment.

Dongwon Bldg. 6F, 333, Yeongdong-daero, Gangnam-gu, Seoul, Republic of Korea, Dongwon Bldg, Gangnam-gu, Seoul, 06188, KR

At Xcell Therapeutics, we believe that scientists and researchers should have the opportunity to develop groundbreaking treatments to cure disease, ensure good health, and limit animal suffering in research. That's why we have develop and produce serum-free, chemically defined media that provides for better research results and greater consistency in manufacturing. Our media is carefully designed and manufactured with precision to help our customers in bioengineering and life sciences achieve a better future for humanity.

111 West Jefferson St., Suite 100, Orlando, FL 32801, US

Xēnix Medical is a surgical implant company focused on the development of novel science-based solutions for patients requiring spinal fusion surgery. The company, headquartered in Orlando, Florida, markets its line of spinal implant devices in the United States through a network of independent distributors.

Indianapolis, Indiana, United States

Mixed Lymphocyte Reactions are cell proliferation assays. We offer a comprehensive selection of MLRs experiments to test your product.

Lund, Skåne, Sweden

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.

Oxford, GB

Yellowstone aims to unlock a new class of therapeutically targetable frequently expressed antigens with potential to significantly transform patient lives. Spun out of the University of Oxford, Yellowstone is built around the pioneering research of Professor Paresh Vyas, a world-renowned scientific academic, key opinion leader and practising clinician with a specialist focus on acute myeloid leukaemia (AML). The Company is headquartered in Oxford, UK, with backing from a leading FTSE 250 healthcare company, Syncona.

Research Triangle Park, North Carolina, United States

ZenBio is a provider of advanced cell-based solutions and services to the life science, cosmetics, and personal care communities, specializing in adipose derived stem cells and human primary cells.